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INTRODUCTION 
 Idiopathic intracranial hypertension is a neurological disorder 
characterized by elevated cerebrospinal fluid pressure without a known cause.  
It is more common in obese women of child-bearing age1 and is uncommon in 
the non-obese, men, elderly and very young children.Though the annual 
incidence of IIH in general population is low (0.9/100,000), the incidence in 
women between 20 and 44 years of age is 3.5/1,00,000 and 19/1,00,000 in 
women who are 20% over weight.2 
 The most common presenting complaints are headache(76%),reduced 
visual acuity(48%),transient obscuration of vision(48%),nausea and vomiting 
(30%), and diplopia (8%)1.The most common visual field defect is an enlarged 
blind spot. Papilledema is the ophthalmologic hallmark of Idiopathic 
intracranial hypertension Neuroimaging is usually normal. Diagnosis is based 
on Modified Dandy criteria. The neurological examination will be normal apart 
from papilledema and a 6th  nerve palsy which is a false localizing sign. 
 The commonly associated risk factors are Hypothyroidism, 
Hyperthyroidism, Obesity, Pregnancy, Anaemia, Hypertension, Obstructive 
sleep apnoea, exposure to exogenous drugs like Tetracyclines, Corticosteroids, 
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Oral contraceptives, Vitamin A intoxication, nalidixic acid and topical 
isotretinoin. Increased intracranial venous pressure related to stenosis of the 
cerebral venous sinuses is another proposed causal mechanism of idiopathic 
intracranial hypertension3 .The treatment includes Weight reduction, Repeated 
lumbar punctures, Carbonic anhydrase inhibitors and Diuretics. Surgical 
treatment includes Optic nerve sheath fenestration, Bariatric surgery, Lumbo-
peritoneal Shunting procedures and Venous sinus stenting. The most important 
metrics when following IIH patients are formal perimetry and fundus 
examination, often augmented by stereo optic disc photographs. 
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ANATOMY OF OPTIC NERVE 
 It is the second cranial nerve. Each optic nerve starts from the optic disc 
and extends upto the optic chiasma, where the two nerves meet. It is the 
backward extension of the nerve fibre layer of the retina which consists of the 
axons originating from the ganglion cells4 
PARTS OF THE OPTIC NERVE  
           The optic nerve is about 47-50mm in length and can be divided into 4 
parts: 
a. Intraocular part (1mm) 
b. Intraorbital part (30mm) 
c. Intracanalicular part (6-9mm) and  
d. Intracranial part (10mm)  
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ANATOMY OF OPTIC NERVE HEAD (INTRAOCULAR 
PART) (OPTIC PAPILLA, OPTIC DISC) 
 The optic nerve head is the distal part of the optic nerve 4. It extends from 
the retinal surface to the myelinated part of the optic nerve just behind the 
sclera and lamina cribrosa. The optic nerve head is so called because of its 
three-dimensional structure.  
COMPOSITION  
 Nerve fibres arise from the ganglion cell layer and converge upon the 
ONH. Connective tissue support is provided by the glial cells and astrocytes. 
The axons at the superior and inferior poles have less structural support. The 
axons exit the globe through a fenestrated scleral canal, the lamina cribrosa. 
Optic nerve diameter expands to about 3mm once the axons become 
myelinated in the retrolaminar part. 
 The optic cup is pale in color due to the visibility of the lamina cribrosa 
and presence of connective tissue. The lamina cribrosa has fenestrations which 
appear as dots. The normal optic disc is vertically oval while the cup is 
horizontally oval and slightly displaced superiorly. The inferior rim is the 
thickest. followed by nasal, temporal being thinnest. 
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     The optic nerve head exhibits three zones 4 namely, 
1. Surface nerve fibre layer 
2. Prelaminar region 
3. Lamina cribrosa 
4. Retrolaminar region 
SURFACE NERVE FIBRE LAYER 
         It contains predominantly of axonal nerve fibres of the ganglion cells 
along with interaxonal glial tissue.  
PRELAMINAR REGION 
         The structures at this level are neurons and a significantly increased 
quantity of astroglial tissue.  
LAMINA CRIBROSA 
          It is a fibrillar sieve like structure made up of fenestrated sheets of scleral 
connective tissue lined by glial tissue. It bridges the posterior scleral foramina 
or the scleral canal. The bundles of optic nerve fibres leave the eye through 
these fenestrations.  
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RETROLAMINAR REGION 
This area is characterised by a decrease in astrocytes and the acquisition 
of myelin that is supplied by oligodendrocytes. The addition of myelin sheath 
nearly doubles the diameter of the optic nerve (from 1.5 to 3.0 mm) as it passes 
through the sclera.  
 
 INTRAORBITAL PART 
  Intraorbital part of the optic nerve  is from behind the globe to the optic 
foramen. This part is sinuous. Important relations of this part are: 
1. The optic nerve in the orbit is covered by duramater, arachnoid and 
piamater.  
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2. The central retinal artery along with the accompanying vein crosses the 
subarachnoid space to enter the nerve on its inferomedial  aspect about 
10mm from the eyeball. 
3.  Near the optic foramen, the optic nerve is closely surrounded by the 
annulus of Zinn  
4. The long and short ciliary nerves and arteries surround the optic nerve 
before these enter the eyeball. 
INTRACANALICULAR PART  
1. This part is closely related to the ophthalmic artery which crosses the 
nerve inferiorly from medial to lateral side in the dural sheath and then 
leaves the sheath at the orbital end of the canal. 
INTRACRANIAL PART 
1. This part of the optic nerve, about 1 cm in length It is ensheathed in 
piamater, but receives arachnoid and dural sheaths at the point of its entry 
into the optic canal4. 
MENINGEAL SHEATHS OF OPTIC NERVE 
1. The intracranial part of the optic nerve is covered by piamater only, while 
the intracanalicular and intraorbital parts of the nerve have three coverings: 
the piamater, arachnoid and duramater. 
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2. The meningeal sheaths and the subarachnoid and the subdural spaces 
around the optic nerve are continuous with those of the brain 4. 
BLOOD SUPPLY OF OPTIC NERVE HEAD 
INTRAOCULAR PART 
a. The surface nerve fibre layer is mainly supplied by the capillaries derived 
from the retinal arterioles, which anastomose with vessels of the 
prelaminar region.  
b. The prelaminar region is supplied by peripapillary choroidal plexus.  
c. The lamina cribrosa region is also supplied by the ciliary vessels which are 
derived from the short posterior ciliary arteries and arterial circle of Zinn-
Haller. 
d. The retrolaminar region is supplied by both the ciliary and retinal 
circulation with the former coming from recurrent pial vessels. The central 
retinal artery provides centripetal branches from the pial plexus and also 
centrifugal branches.  
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BLOOD SUPPLY OF OPTIC NERVE HEAD 
INTRAORBITAL PART 
 The intraorbital part of optic nerve is supplied by two systems of 
vessels-a periaxial and an axial: 
a. The periaxial system of vessels supplying this part of optic nerve is 
derived from the six branches of internal carotid artery namely: 
ophthalmic artery, long posterior ciliary arteries, short posterior ciliary 
arteries, lacrimal artery and central artery of retina before it enters the 
optic nerve and circle of Zinn. 
b. The axial system of vessels supplying the axial part of the optic nerve is 
derived from:  
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1) the intraneural branches of the central retinal artery 
2) central collateral arteries which come off from the central 
retinal artery before it pierces the nerve and  
3) central artery of optic nerve. 
INTRACANALICULAR PART 
 The nerve within the optic canal is supplied only by the periaxial system 
of vessels. The pial plexus in this part is fed mainly by branches from the 
ophthalmic artery. 
INTRACRANIAL PART 
Intracranial portion is exclusively supplied from the periaxial system of 
vessels. The pial plexus here is contributed by 4 sources: 
1) branches from the internal carotid artery either directly or through the 
recurrent branch of anterior superior hypophyseal artery(supply the 
inferior aspect of the optic nerve containing lower retinal fibres) 
2) branches from anterior cerebral artery (supply the superior aspect of the 
optic nerve containing upper retinal fibres), 
3) small recurrent branches from the ophthalmic artery and, 
4) the twigs from the anterior communicating artery. 
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VENOUS DRAINAGE 
A. The venous return in the optic nerve head is primarily by the central 
retinal vein. 
B. The orbital part is drained by peripheral pial plexus and also by central 
retinal vein in the distal part. 
C. The intracranial part is drained by the pial plexus which ends in anterior 
cerebral and basal vein. 
Ø Autoregulation 
Ø Presence of blood-brain barrier4. 
CIRCULATION OF CEREBROSPINAL FLUID 
         
Formed by the choroid plexus 
in the ventricles of the brain
Third ventricle 
Fourth ventricle
Subarachnoid space 
Foramina of Munro
Sylvian aqueduct 
Foramina of Luschka and 
Magendie 
Some flowing around the 
spinal cord and the rest 
bathing the cerebral 
hemisphere
Absorption is into the 
cerebral venous drainage 
system through the 
arachnoid vili
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CEREBRAL VENOUS SINUSES 
Dural venous sinuses are venous channels located intracranially between 
the two layers of duramater (endosteal layer and meningeal layer). Unlike other 
veins in the body they run alone, not parallel to arteries. They are valveless, 
allowing for bidirectional blood flow in intracranial veins. They form the major 
drainage pathways from the brain. 
The main dural venous sinuses are: 
UNPAIRED 
1. Occipital sinus 
2. Straight sinus 
3. superior sagittal sinus 
4. inferior sagittal sinus 
5. basilar venous plexus 
6. anterior intercavernous sinus 
7. posterior intercavernous sinus 
PAIRED 
1. sigmoid sinus 
2. transverse sinus 
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3. cavernous sinus 
4. inferior petrosal sinus 
5. superior petrosal sinus 
6. sphenoparietal sinus 
7. petrosquamous 
8. middle meningeal 
TRANSVERSE SINUS 
  The superior sagittal sinus, the occipital sinus and the straight sinus are 
drained by transverse sinus and empties into the sigmoid sinus which in turn 
ends in the jugular bulb 
Variant anatomy 
Ø 39% Hypoplasia of left sinus 
Ø 20% Aplasia of left sinus 
Ø 31% Symmetrical 
Ø 6% Aplasia of right sinus 
Ø 4% Hypoplasia of right sinus 
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SIGMOID SINUS 
 The right and left sigmoid sinuses are continuation of the corresponding 
transverse sinuses and become the sigmoid sinus. Here the sinus receives the 
superior petrosal sinus. It ends in the jugular bulb in the posterior half of 
jugular foramen. 
 
 
AXOPLASMIC TRANSPORT 
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      This Process is responsible for the supply of the nutrients within  the axons. 
Ø Axoplasmic Flow  
o Antegrade flow 
o Retrograde flow 
o Fast & slow components  
 Constant antegrade and retrograde flow of materials is necessary for the 
maintenance of the axons. 
NORMAL AXOPLASMIC FLOW 
 Slow component 
Ø 1 – 3 mm per day 
Ø Driven by the peristaltic wave  
Rapid component  
Ø Pass through disc quickly and evenly 
Ø 400 mm per day 
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FACTORS INFLUENCING AXOPLASMIC FLOW 
Ø   Intra axonal pressure 
Ø   Intra ocular pressure 
Ø Optic Nerve Tissue pressure (ONTP) 
Ø CSF pressure 
CAUSES OF RAISED INTRAOCULAR PRESSURE 
Blood 
§ Hemorrhage 
§ Obstruction of venous outflow (cerebral venous thrombosis) 
Brain 
§ Mass lesions (tumor, abscess) 
§ Cerebral edema (trauma, Hypoxic ischemic encephalopathy, 
electrolyte abnormalities, metabolic abnormalities, meningitis) 
CSF 
§ Increased production (choroidal plexus papilloma-rare) 
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§ Decreased drainage (communicating/non-communicating 
hydrocephalus,  shunt malfunction) 
Idiopathic 
§ Idiopathic intracranial hypertension (Pseudo-tumor Cerebri)   
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PAPILLOEDEMA 
 Papilledema is a passive, non-inflammatory, hydrostatic edema of the 
optic nerve head due to increased intracranial pressure. 
 It is almost always bilateral and asymmetrical5.  
 NORMAL OPENING PRESSURE ON LUMBAR PUNCTURE 
INFANTS - <80 mmH2O 
CHILDREN - <90 mmH2O 
ADULTS - <210 mmH2O5 
DIAGNOSIS OF RAISED INTRACRANIAL PRESSURE 
1. Headaches-more severe in the morning, worsening progressively. 
Intensifies with head movement. 
2. Sudden nausea and vomiting, often projectile, may partially relieve the 
headache.  
3. Deterioration of consciousness may be slight, with drowsiness and 
somnolence. Dramatic deterioration of consciousness is indicative of 
brainstem distortion with tentorial or tonsillar herniation and requires 
prompt attention. 
26 
 
4. Visual symptoms 
a. Transient Obscurations lasts usually for five seconds, rarely exceeds 
30 seconds at irregular intervals  
b. Horizontal diplopia due to abducent nerve paresis caused by stretching 
of one or both 6th nerves over the tip of petrous temporal bone; this is 
therefore a false localizing sign5. 
c. Visual loss occurs late with secondary optic atrophy due to long-
standing papilledema. 
5.Investigations 
 MRI, CT and B-SCAN show an enlarged optic nerve diameter. 
VISUAL FIELD DEFECTS COMMON IN PAPILLEDEMA 
1. Enlargement of blind spot 
2. Concentric contractions 
3. Relative scotoma first to green and red 
4. Complete blindness 
5. Homonymous hemianopia 
6. Central and arcuate scotomas 
7. Infero-nasal quadrant -most commonly involved 
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THEORIES OF PAPILLEDEMA 
EARLIER THEORIES 
1. Non-mechanical  
2. Inflammatory by Gowers and Leber 
3. Vasomotor theory by Kornder 
MECHANICAL THEORY 
1. Venous obstruction 
2. Obstruction of tissue fluid 
3. Forcing of CSF into optic nerve 
MODERN THEORY 
1. Hayreh’s Theory of axoplasmic stasis (most accepted theory) 
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MECHANISM OF PAPILLEDEMA 
 
 
 
 
 
 
 
 
 
PAPILLEDEMA
AXOPLASMIC STASIS
ARREST OF AXOPLASMIC TRANSPORT
ALTERATION OF PRESSURE GRADIENT ACROSS LAMINA CRIBROSA
RAISED OPTIC NERVE TISSUE PRESSURE
INCREASED CSF PRESSURE
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MECHANISM BY WHICH VENOUS STENOSIS CAUSES 
PAPILLEDEMA 
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Hayreh’s Theory
Raised ICT
Raised CSF 
pressure
around optic 
nerve
Percolation of CSF 
into optic nerve
Raise of optic nerve 
tissue pressure
Alternation of 
pressure 
gradient across 
lamina cribrosa
Axonal swelling
Swelling of optic 
nerve head
Stasis and 
accumulation 
of Axoplasm
 
FUNDUS SIGNS IN OPTIC DISC EDEMA 
MECHANICAL SIGNS: 
1. Optic nerve head swelling 
1mm  disc elevation  causes+3D refractive change. 
2. Blurring of optic disc 
3. Filling of the physiological cup: 
It occurs due to axons crowdind  leading to narrowing of the optic cup. 
4. Edema of the peripapillary nerve fibre layer6 
5. Retinal or choroidal folds: 
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These occur in the peripapillary area and the posterior pole. Linear lines 
which develop are also referred to as Paton’s lines6. 
VASCULAR SIGNS 
Disc hyperemia 
Ø It is due to an increased vascularity of the disc and opening up of the 
smaller blood vessels on the  surface of the disc. 
Ø This leads to an increase in the Kestenbaum’s number (number of 
small vessels traversing the optic disc)6. This becomes more than 12 
in disc hyperaemia. 
Vascular congestion  
(Venous dilatation and tortuosity): 
 It is due to reduction in the venous outflow and increased pressure 
within the venules.   
Peripapillary haemorrhages: 
 These occur due to rupture of small blood vessels. 
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Exudates in the disc or peripapillary area: 
 This occurs due to leakage of proteins and lipids from congested blood 
vessels. 
Nerve fibre layer infarcts: 
Ø This appears as areas of pale edema in the peripapillary areas. 
GRADING OF PAPILLEDEMA 
EARLY PAPILLEDEMA 
1. Disc swelling 
2. Disc hyperemia 
3. Blurring of optic disc margins. 
4. Blurring of the peripapillary nerve fibre layer 
5. Dilatation of retinal veins 
6. Absence of spontaneous venous pulsations 
ESTABLISHED PAPILLEDEMA  
1. Increase in disc swelling(2 to 6 dioptres) 
2. Peripapillary chorio-retinal folds 
3. Venous engorgement, splinter hemorrhages and microaneurysms 
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4. In advanced cases, amyloid bodies may develop over the disc surface. 
  CHRONIC PAPILLEDEMA  (Vintage papilledema) 
1. Resolved hemorrhages, exudates and edema over the disc. 
2. The disc hyperaemia and haemorrhages reduce. 
3. Disc edema persists in this stage for months to years without any change. 
4. Classically,  it appears as “CHAMPAIGNE CORK”. 
5. The disc eventually becomes dirty gray and pale in color. 
6. Optociliary shunts and drusen like deposits may be present on the disc. 
ATROPHIC DISC EDEMA 
1. Grey white pallor of disc with blurred margins 
2. Attenuated sheathed vessels 
3. The resolving edema may leave “WATER MARKS”. 
4. Gliosis on the disc surface and margins 
HISTOPATHOLOGICAL FINDINGS IN PAPILLEDEMA6 
1. Edema and vascular congestion. 
2. Peripapillary haemorrhages. 
3. Obliteration of the optic cup. 
4. Disc elevation into the vitreous cavity. 
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5. Engorgement and tortuosity of the small blood vessels. 
6. Accumulation of the extracellular fluid in and anterior to the retinal 
lamina cribrosa 
7. Enlargement of the subarachnoid space, with stretching. 
8. Engorgement of axons in the prelaminar portion. 
Electron microscopy of these axons shows:  
Ø Axonal swelling and accumulation of mitochondria. 
Ø Mitochondrial swelling and disruption. 
Ø Disruption of fascicles of the microtubules. 
9. Peripapillary sensory retinal changes include: 
Ø Displacement of the retina away the disc. 
Ø Buckling of the outer layers of the retina. 
Ø Displacement of the rods and cones away from their anchor  near 
Bruch’s membrane. 
Ø Serous retinal detachment in the peripapillary area may occur. 
10. Chronic disc edema is characterised by degenerative and fibrotic 
changes. 
11. Established papilledema shows secondary optic atrophy with subsequent 
gliosis and fibrotic. 
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FRISEN’S GRADING SYSTEM2 
a. Stage 0: 
1. Mild nasal elevation of nerve fibre layer 
2. A portion of major vessels obscured in upper pole. 
b. Stage 1: Very early papilledema 
Ø Obscuration of nasal border of disc 
Ø No elevation 
Ø Disruption of nerve fibre layer 
Ø Concentric or radial retinal halo 
      c. Stage 2: Early papilledema 
o obscuration of all borders 
o elevation of nasal border 
o complete peripapillary halo 
      d. Stage 3: Moderate papilledema 
o Obscuration of all the borders 
o Increased diameter of optic nerve head 
o Obscuration of one or more segments of major blood vessels                
leaving the disc 
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        e. Stage 4: Marked papilledema 
o Elevation of the entire nerve head 
o Obscuration of all the borders 
o Peripapillary halo 
o Total obscuration on the disc of a segment of major blood vessels 
        f. Stage 5:  Severe papilledema 
o Dome shaped protrusions representing anterior expansion of optic 
nerve head 
o Peripapillary halo 
o Total obscuration of a segment of major blood vessels 
o Obliteration of optic cup 
o Obscuration of all the borders 
PSEUDOPAPILLEDEMA 
  Disc appearance resembling disc edema, in the absence of a true disc 
edema6. 
Features of pseudopapilledema:6 
a. Absence of central cup but presence of venous pulsation. 
b. Vessels arise from the central apex of the disc. 
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c. Anomalous branching of the vessels on the disc and increased number of 
major disc vessels. 
d. Disc transillumination shows drusens. 
e. Disc margins show irregular outline Absence of superficial capillary 
telangiectasia, haemorrhages, exudates and cotton wool spots. 
f. Absence of peripapillary retinal folds. 
g. Lack of fluorescein leakage from disc vessels. 
h. Drusen shows autofluorescence in FFA prior to dye injection and stains 
in the late stages of the angiogram. 
DD FOR PSEUDOPAPILLEDEMA 
1. Small hypermetropic disc 
2. Optic nerve head drusens 
3. Medullated nerve fibres 
  
 
 
 
 
 
38 
 
IDIOPATHIC INTRACRANIAL HYPERTENSION 
INTRODUCTION 
Idiopathic intracranial hypertension is a syndrome characterised by 
elevated intracranial pressure without ventriculomegaly or mass lesion, and 
with normal cerebrospinal fluid composition that usually occurs in obese 
women of child-bearing age. It is a disorder of elevated CSF pressure. It is 
often referred to as “Pseudotumour cerebri”7 
  Quinke in 1897 reported the first cases of IIH. It was named 
Pseudotumour Cerebri in 1904. Initially the term Benign intracranial 
hypertension was coined by Foley in 1955. 
 The underlying cause is reduced absorption of cerebrospinal fluid. The 
ventricular system is normal without any deformity and obstruction. The 
neuroimaging  is normal except for raised CSF pressure. 
 The CSF pressure is above 200mm of water in the non-obese and above 
250mm of water in the obese. 
 The peak incidence is in the 3 rd decade of life, especially obese females 
in the reproductive age group. 
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 The most common presenting symptoms of raised intracranial pressure 
are headache, pulsatile tinnitus, transient obscuration of vision, pain behind the 
eyes, double vision and loss of vision. 
 Signs are diplopia due to abducent nerve paresis and papilledema 
resulting in loss of sensory visual function. 
   Most Common visual field defect is an enlarged blind spot. 
      This satisfies the modified Dandy criteria for IIH. 
 Neuroimaging signs include empty sella syndrome, lateral or transverse 
sinus stenosis, flattening of  globe and unfolding of optic nerve sheaths. 
CRITERIA FOR DIAGNOSIS (MODIFIED DANDY CRITERIA)8 
1. “Signs and symptoms of increased intracranial pressure headaches, 
nausea, vomiting, transient obscurations of vision, papilledema). 
2. No localising, focal neurologic signs, except unilateral or bilateral sixth 
nerve paresis. 
3. Cerebrospinal fluid opening pressure ≥ 25 cm, but without cytologic or 
chemical abnormalities. 
4. Normal neuroimaging results adequate to exclude cerebral venous 
thrombosis, i.e., magnetic resonance imaging of the brain, often with 
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additional sequences (computed tomography or magnetic resonance 
venography).” 
EPIDEMIOLOGY 
   The annual incidence in general population is 0.9/1,00,000  and  
3.5/1,00,000 females. In obese women aged 25 to 40 years, the incidence is 
19/1,00,000. The female to male ratio is 2:1. More than ninety percent of IIH 
patients are obese and more than ninety percent are women of child-bearing 
age2. 
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ETIOLOGY 
1. Usually idiopathic in over 90% cases 
2. In 10% cases, in men and non-obese, 
Obstruction to cerebral venous drainage 
Endocrine and metabolic dysfunction 
Exposure to exogenous drugs 
Systemic illness 
ASSOCIATIONS OF IDIOPATHIC INTRACRANIAL 
HYPERTENSION6 
1. Obstruction or impairment of cerebral venous drainage: 
        Tumours 
        Septic thrombi 
        Radical neck dissection 
2. Endocrine and Metabolic Dysfunction: 
Elevated oestrogen levels 
During pregnancy (especially the 2nd and the 5th month) there is decrease 
in the adrenal corticoids and increased oestrogen. 
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Hypoparathyroidism and associated hypocalcemia interferes with 
transport of CSF through arachnoid granulations. 
3. Exogenously administered agents: 
        Systemic steroid therapy leads to suppression of the adrenal cortex. 
         Antibiotics (tetracycline, nalidixic acid) 
         Anti-inflammatory agents: (Indomethacin, Ketoprofen) 
         Vitamin A - hypervitaminosis 
         Lead encephalopathy causes cerebral edema and raised ICT. 
4. Systemic illness: 
        Meningitis and encephalitis lead to blockage of ventricular system. 
         Status epilepticus leads to cerebral hypoxia and cerebral edema. 
         Vascular Hypertension. 
         Thrombocytopenic purpura. 
         Chronic respiratory insufficiency, hypercapnia, reduced blood oxygen, 
polycythemia, elevated venous pressure and ICT. 
5. Familial Benign intracranial hypertension 
6. Obstructive sleep apnoea 
7. Iron deficiency anemia 
8. Thyroid replacement therapy  
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PATHOGENESIS 
 
CLINICAL FEATURES 
SYMPTOMS 
1. Headache 
2. Transient visual obscuration 
3. Pulsatile tinnitus 
4. Flashes of  light 
5. Double vision 
6. Loss of vision 
7. Nausea and vomiting 
HEADACHE:  
1. Usual presenting symptom 
IDIOPATHIC INTRACRANIAL HYPERTENSION
DECREASED CSF OUTFLOW
DYSFUNCTION IN THE ABSORPTION OF CSF
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2. Severe daily pulsatile 
3. May awaken the patient from sleep 
TRANSIENT VISUAL OBSCURATIONS 
1. Usually 5 seconds rarely exceeds 30 seconds 
2. Followed by recovery of vision to baseline 
3. Monocular or binocular 
4. They are due to transient compression or ischemia of the optic nerve 
head  
PULSE-SYNCHRONOUS TINNITUS 
1. Pulsatile intracranial noises often unilateral 
2. The noise is abolished by jugular compression or head turning ipsilateral 
to the sound . 
VISUAL LOSS 
1. Relatively mild at presentation 
2. Best corrected visual acuity ranges from 6/6 to perception of light. 
OCULAR MOTILITY DISTURBANCES 
1. Horizontal diplopia is seen  
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2. Sixth nerve palsy is found in 10 to 20% of cases. 
3. Transient Bell’s type palsies of seventh cranial nerve rarely occur. 
4. The cranial nerves which make nearly a 90 degree bend (CN 2, CN 6, 
CN 7) are more prone for damage at the site of the bend. 
FALSE LOCALISING SIGNS 
ABDUCENT NERVE PALSY 
    Raised intracranial pressure causes sixth nerve palsy. More susceptibility to 
damage is due to its sharp bend over the superior border of the petrous 
temporal bone and the downward shift of the brainstem towards foramen 
magnum produced by raised intracranial pressure. 
PAPILLEDEMA 
1. It is due to raised intracranial pressure. 
2. It is the hallmark of Idiopathic intracranial hypertension8. 
3. It is the cardinal sign of IIH. 
4. It may be bilateral, asymmetrical, or even unilateral. 
5. It is the cause of visual loss in IIH patients. 
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PERIMETRY 
1. Visual field defects occur in almost all cases of Idiopathic intracranial 
hypertension. 
2. Most common visual field defects are 
a. Enlargement of blind spot. 
b. Inferior nasal step defect. 
c. Arcuate defects. 
3. visual field loss may be progressive and severe 
4. The earliest visual field defect-inferior nasal step  
5. Blind spot enlargement is ubiquitous in IIH. 
FEATURES OF FULMINANT IIH: 
1. Rapid onset of symptoms 
2. Significant visual loss 
3. Macular edema 
4. Cerebral venous thrombosis 
5. It requires rapid treatment 
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MECHANISMS THAT LEAD TO DAMAGE OF THE OPTIC DISC 
ARE: 
       1. Disruption of axonal transport 
       2. Intraneuronal optic nerve ischemia 
DISRUPTION OF AXONAL TRANSPORT 
Ø -Raised cerebrospinal fluid pressure disturbs the normal gradient between 
intraocular and retrolaminar pressure. 
Ø This leads to raised optic nerve tissue pressure. 
Ø This finally results in axoplasmic stasis 
Ø This results in intra-axonal edema. 
INTRANEURONAL OPTIC NERVE ISCHEMIA 
Ø High CSF pressure is transmitted to the region posterior to the optic nerve 
sheath. 
Ø This increases the optic nerve tissue pressure 
Ø This disturbs the pressure gradient across the lamina cribrosa. 
Ø This results in axoplasmic flow stasis and compression of small arterioles. 
Ø This finally results in intraneuronal ischemic damage to the optic nerve. 
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CAUSES OF LOSS OF VISUAL ACUITY IN IIH7 
1. Chronic (atrophic) papilledema. 
2. Chorioretinal folds. 
3. Macular edema or exudates 
4. Infarction of the optic disc 
5. Subretinal peripapillary hemorrhage extending through the fovea 
6. Subretinal peripapillary neovascular membrane 
RISK FACTORS FOR VISUAL LOSS7 
1. Recent weight gain 
2. High grade papilledema 
3. Atrophic papilledema 
4. Subretinal hemorrhage 
5. Significant visual field loss at presentation 
6. hypertension 
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EVALUATION AND INVESTIGATIONS 
1.NEUROIMAGING 
Normal  neuroimaging is a essential for the accurate diagnosis of IIH. 
MAGNETIC RESONANCE IMAGING: 
MRI with or without contrast is the best investigation of choice. 
a. MRI Angiography 
b. MRI Venography 
Ø To rule out arterial disease and venous obstruction(thrombosis) 
Ø Arnold-Chiari malformations 
Ø To see structured lesions( mainly posterior fossa lesions) 
Ø To see hydrocephalus  
Ø Fascial resolution is better in MRI which provides three-   dimensional 
image. 
Ø Soft tissue lesions are well appreciated 
Ø Magnetic resonance venogram is the procedure of choice for diagnosis 
of dural venous sinus thrombosis. 
Ø On neuroimaging few patients show evidence of stenosis of one or both 
transverse sinuses. 
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COMPUTED TOMOGRAPHY 
a. To rule out intracranial lesions that would produce increased intracranial 
pressure and rule out obstructive hydrocephalus. 
Ø Acute vascular causes- like subarachnoid, epidural, subdural, 
intracranial haemorrhages, acute infarctions. 
Ø After head injury- cerebral edema 
     b. Patient with contraindication to MRI like pacemaker, metallic clip and 
metallic foreign body. 
  2. LUMBAR PUNCTURE 
a. Diagnostic- to evaluate for intracranial hypertension by recording the 
opening pressure. 
b. To send CSF for microbial/infectious studies like-Total leukocyte, 
differential count, glucose, protein, cytology and VDRL. 
c. Therapeutic-pseudotumor cerebri. 
It is usually contraindicated because of the danger of herniation of the 
brain into the foramen magnum which causes pressure on medulla 
leading to sudden death in cases with intracranial space occupying 
lesions with midline shift. 
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COMPLICATIONS OF LUMBAR PUNCTURE ARE: 
1. Poor compliance 
2. Painful 
3. Difficult in obese patients 
4. May produce a remission of Pseudotumor cerebri by creating a 
permanent fistula through the duramater. 
5. Spinal epidermoid tumors 
6. Infection 
A CSF pressure more than 250mm H2O is consistent with the 
diagnosis. 
The upper limit of CSF pressure in children is generally considered 
to be 180-200 mmH2O. 
    3. VISUAL FIELDS TESTING BY PERIMETRY 
Ø Quantitative perimetry with kinetic perimetry for the peripheral field. 
Ø Automated static perimetry for central fields. 
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MONITORING OF THE OPTIC NERVE HEAD 
Ø Fundus photography is performed at the first evaluation and then whenever 
there is a change to provide the examiner with objective evidence of the 
appearance of the optic disc. 
Ø Confocal scanning tomography is a new method to quantify the degree of 
papilledema. 
     5. CONTRAST SENSITIVITY 
Ø It is a sensitive technique to record the optic nerve dysfunction. 
    6.VISUAL EVOKED POTENTIALS 
Ø It is a useful tool but not routinely employed. 
    7.ULTRASONOGRAPHY 
Ø It can be used to assess the diameter of the retrobulbar optic nerves as 
a measure of intracranial pressure. 
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 X-RAY FINDINGS IN PAPILLEDEMA: 
   IN ADULTS: 
a. Demineralisation of subcortical bone leading to loss of “lamina dura” 
(white line) of sellar floor followed by thinning of dorsum sella and the 
posterior clinoid process. 
b. In extreme cases the sella becomes very shallow and flattened with its 
floor and anterior wall demineralised and the posterior clinoid process and 
dorsum sella destroyed. 
c. Increased intracranial tension causes enlargement of the emissary veins in 
occipital region. 
d. Congenital cyst or chronic subdural hematoma may show localised 
thinning or bulge. 
X-RAY FINDINGS IN CHILDREN: 
a. Presents with sutural diastasis, (sutural widening) 
b. Increased convolutional markings with thinning of the bone. 
c. Any separation beyond 2 mm is suspicious of increased tension. 
d. Silver beaten appearance-due to pressure of sulci and gyri. 
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FUNDUS FLUORESCEIN ANGIOGRAPHY FINDINGS OF 
PAPILLEDEMA: 
EARLY PHASE: 
Ø Disc capillary dilatation 
Ø Dye leakage spots 
Ø Microaneurysms over the disc 
   LATE PHASE: 
Ø Leakage of dye beyond disc margin 
Ø Pooling of dye around the disc as vertically oval pooling 
    MRI FINDINGS IN IIH 
1. Slit like ventricles 
2. Optic nerve findings 
a. Prominence of subarachnoid space around the optic nerve 
b. Papilledema 
c. Flattening of the posterior sclera 
d. Vertical tortuosity of the optic nerves 
e. Enhancement of prelaminar optic nerves 
3. Partial empty sella turcica 
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4. Small meningoceles (region of geniculate ganglion and orbital apex) 
5. Prominent arachnoid pits (lateral sphenoid) 
6. Transverse sinus stenosis is seen in MRA. 
EMPTY SELLA 
a.  It is associated with prolonged rise in IOP 
b. It is due to downward herniation of arachnocele through the 
diaphragm sellae. 
POSTERIOR GLOBE FLATTENING 
a. This is seen in both CT and MRI studies 
b. It is the sine qua non neuroimaging sign of Pseudotumor cerebri 
c. This is related to both raised intracranial as well as intraocular 
pressure. 
CSF STUDIES: 
To find the opening pressure and to rule out infective and neoplastic causes of 
Papilledema. 
HUMPHREY FIELD ANALYSER 
Ø It is the most frequently used automated perimeter5. 
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Ø It is a type of static perimetry in which the location of a stimulus   
remains fixed at a certain location within the field, with the intensity 
increased until it is seen by the subject. 
Ø The target intensity is increased until threshold is reached. 
METHOD: 
     HFA consists of a hemispherical bowl onto which a target can be projected 
at any location in the visual field. 
1. Monitor on the side of the instrument presents a series of menus. 
Background luminance is set at 31.5 asb, considered to be at the lower 
end of the photopic illumination range. 
2. Variation in stimulus intensity can be achieved by altering target size or 
luminance. Size is set prior to the test; 4 sq.mm is used routinely. 
3. Luminance is altered between 0.08 asb and 10 000 asb brighter than the 
background: between 51 dB and 0 Db. 
a. In 30-2, the area tested extends to 30 degrees temporally as well as 
nasally. 
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RELIABILITY INDICES: 
These reflect the extent to which patient’s results are reliable. They 
should be analysed first. In patients who consistently fail to achieve 
good reliability indices, they can be switched over to a suprathreshold 
strategy or kinetic perimetry. 
1. Fixation losses: 
   They indicate steadiness of gaze during the test. A gaze monitor is 
used in newer HFAs. 
2. False positives: 
    These are detected in when a stimulus is accompanied by a sound. The 
grey scale printout appears pale. 
3. False negatives: 
     These are detected by presenting a stimulus much (9 dB) brighter 
than threshold at a location where the threshold has already been 
determined. If the patient fails to respond a false negative is recorded. A 
high false negative score indicates inattention or tiredness. The grey 
scale printout in individuals with high false negative responses tends to 
have a clover-leaf shape. 
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4. Interpretation: 
With SITA strategies, false negatives or false positives about 15% 
should be regarded as highly significant. With full-threshold strategies, 
fixation losses over 20% and false positives or negatives over 33%. 
 
HUMPHREY’S FIELD ANALYSER 
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MANAGEMENT OF IDIOPATHIC INTRACRANIAL 
HYPERTENSION 
A. Treatment depends on the course of idiopathic intracranial hypertension. 
B. When IIH is associated with an identified causal triggering factor, such as 
anemia, excessive vitamin A, Tetracyclines, obstructive sleep apnoea, 
withdrawal of the offending drug or treatment of the triggering factor often 
results in rapid improvement. 
C. Main goals of the treatment are: 
a. To preserve vision 
b. To alleviate symptoms of raised intracranial pressure especially headache 3. 
D. Management is requires history, examination and clinical course. 
E. The most important factor is the amount of vision loss and the severity of 
patient’s symptoms that disrupts their activities of daily living. 
MEDICAL MANAGEMENT 
  It is aimed at reducing the intracranial pressure and relieving the patient 
of the distressing symptoms. 
 
60 
 
WEIGHT LOSS 
 Weight loss is a crucial in the treatment of overweight and obese patients 
with IIH3. A modest degree of weight loss is required for improvement in 
symptoms and signs (5% to 10% of total body weight). Low sodium diet and 
mild restriction of fluids is useful in some patients. 
LUMBAR PUNCTURE 
 The treatment of IIH begins with the diagnostic lumbar puncture. The 
opening CSF pressure should be measured in the relaxed, lateral decubitus 
position without sedation to avoid spurious elevations of intracranial pressure. 
Smooth walled venous sinus stenosis resolve with lowering the CSF pressure. 
LP needle creates a sieve that allows sufficient regress egress of CSF, so that 
ICT is normalised. 
INDICATIONS 
DIAGNOSTIC 
1. Infectitious 
2. Inflammatory 
3. Neoplastic 
4. Meningitis 
5. Subarachnoid hemorrhage 
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THERAPEUTIC 
1. Hydrocephalus 
2. Idiopathic intracranial hemorrhage 
3. Spinal anaesthesia 
4. Chemotherapy 
CONTRAINDICATIONS 
1. Uncal herniation 
2. Skin infection at the puncture site 
3. Sepsis 
CORTICOSTEROIDS 
 Their use remains unclear in IIH. There is usually a recurrence of disc 
edema with rapid tapering of the dose. Use of long-term steroids is abandoned. 
They can be used for short-term treatment preoperatively before a CSF 
shunting procedure. Prednisolone is started at a dose of 2mg/kg/day in those 
who are intolerant to high doses of acetazolamide. This is given for two weeks 
and weaned over the next two weeks. Blood pressure, electrolytes, and urine 
glucose are monitored regularly. 
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ACETAZOLAMIDE 
 It is the most common drug used in the treatment of IIH. It is a carbonic 
anhydrase inhibitor. It decreases production of CSF at the level of the choroid 
plexus. It is usually started at a dose of 0.5 to 1 g/day and gradually increased 
until clinical improvement is seen. It also causes anorexia aiding in weight loss. 
TOPIRAMATE 
 Topiramate is an alternative drug for IIH. It is primarily an anti-
convulsant. It is a partial carbonic anhydrase inhibitor. It is effective for  
headaches such as migraine. It has weight loss as a prominent side effect.  
FUROSEMIDE 
 It is a second line treatment. It is a loop diuretic. It lowers the 
intracranial pressure by both diuretic effect and reducing transport of sodium 
into the brain. Potassium supplementation is given as needed. It is initiated at a 
dose of 20mg BD and gradually increased to a maximum of 40mg TID. 
SURGICAL THERAPY 
 These are mainly for treating refractory IIH. 
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CSF DIVERSION TECHNIQUES 
1. Lumboperitoneal shunting 
2. Ventriculoperitoneal shunting 
NON-CSF DIVERSION TECHNIQUES 
1. Optic nerve sheath fenestration 
2. Induced weight loss by bariatric surgery 
3. Venous  sinus stenting 
CSF shunting procedures: 
They are mainly useful in cases of 
a. Failed medical treatment 
b. Medically intractable headache 
The problems associated with this procedure are 
a. Mechanical shunt dysfunction 
b. Infections 
c. Need for repeated revisions 
d. High failure rate 
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The stereotactic ventriculoperitoneal shunting technique is recently 
introduced method. It is minimally invasive method. 
OPTIC NERVE SHEATH DECOMPRESSION 
It consists of creating a fenestration in the dural sheath just behind the 
globe. Exact mechanism is uncertain. It may be due to CSF egress forming a 
fistula thereby preventing transmission of high CSF pressure to the optic nerve 
head. 
       Loss of vision is a serious complication of idiopathic intracranial 
hypertension. Outcomes are to improve or stabilise the visual function. Optic 
nerve sheath decompression is an effective and safe surgical procedure to 
improve vision in patients with IIH. Optic nerve sheath decompression helps 
in relieving headache and improving visual acuity. 
INDICATIONS FOR DECOMPRESSION 
1. Failure of medical treatment as evidenced by clinical signs such as 
Ø Marked degree of swelling (>5D) 
Ø Great engorgement of veins 
Ø Presence of extensive hemorrhage 
Ø Early appearance of exudates spots 
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2.  Progressive headaches unrelieved with medical treatment 
3.  Progressive optic neuropathy evidenced by early contraction of visual field.  
4.  Severe or rapid loss of vision at the onset, relative afferent papillary defect 
or signs of advanced optic nerve dysfunction. 
5.  Severe papilledema causing macular edema or exudates.  
APPROACHES 
1.  Medial transconjunctival orbitotomy 
2. Lateral orbitotomy 
3. Lateral canthotomy 
PROCEDURE 
      In this procedure, a window or multiple sites are made in the dural sheath 
of the optic nerve immediately behind the globe. This immediately reduces 
pressure on the nerve by creating a filtration apparatus that controls the 
pressure surrounding the orbital segment of the optic nerve. 
MECHANISM 
1.  The filtering effect with local cerebrospinal fluid pressure reduction 
improving the peripapillary circulation. 
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2.  Generalised decrease in the intracranial pressure after optic nerve 
sheath decompression. 
3. The scarring of the arachnoid that may protect the optic nerve head 
from elevated cerebrospinal fluid pressure. 
 COMPLICATIONS OF ONSD 
1. Extraocular motility restriction-commonly involves lateral rectus. 
2. Pupillary dysfunction. 
3. Loss of vision from vascular occlusion 
4. Visual field defects 
5. Orbital hemorrhage 
6. Transient or protracted blindness 
7. Globe perforation 
OTHER DISC DECOMPRESSION TECHNIQUES TO RELIEVE 
PAPILLEDEMA ARE: 
1. Subtemporal decompression 
2. Suboccipital craniectomy 
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BARIATRIC SURGERY 
 It is a gastric exclusion procedure. It essentially treats comorbid 
conditions in obesity such as arterial hypertension, diabetes mellitus, and sleep 
apnoea. A neuro-endocrine basis is proposed for the benefits of this procedure. 
It produces a durable remission in IIH. 
VENOUS SINUS STENTING 
  Neuroimaging shows narrowing or stenosis of transverse venous sinuses 
in a large number of IIH patients. Collapse of the transverse sinus is ubiquitous 
in IIH and obstructs venous return. This stenting procedure reduces cerebral 
venous pressure, reduces intracranial pressure, and improves the symptoms 
and signs. There is a persistent debate as to whether these venous 
abnormalities are cause or consequence of increased intracranial pressure.  
MANAGEMENT OF PREGNANCY INDUCED HYPERTENSION 
WITH PAPILLEDEMA 
1. Bed rest 
2. Diet restriction 
3. Sedatives like phenobarbitone/diazepam 
4. Control of blood pressure 
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5. Control edema- proteinuria/diuretic/hypertonic glucose 
6. Finally if patient does not respond to treatment, pregnancy has to be 
terminated. 
  TREATMENT OF FULMINANT IIH 
1. intravenous corticosteroids 
2. insertion of lumbar drain 
  DETERMINATION OF THERAPEUTIC SUCCESS 
1. relief of headache 
2. diminished frequency of transient visual obscuration 
3. regression of papilledema 
4. stability or improvement of field defects 
5. weight reduction 
OVERALL MANAGEMENT PROTOCOL 
1. No symptoms of papilledema 
Ø periodic monthly review 
Ø if vision normal for 3 months, then 2-monthly review 
          2. With transient obscuration of vision/signs of optic nerve dysfunction 
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Ø Acetazolamide 1g daily depending on patient’s tolerance 
Ø Re-examine the patient every 2 to 3 weeks for signs of compromise 
           3. With progressive optic neuropathy 
Ø Acetazolamide- corticosteroid (80 to 100 mg/day)  
           4. Other treatment modalities reserved for refractory cases 
Ø Repeated lumbar puncture 
Ø Lumboperitoneal shunt 
Ø Optic nerve sheath decompression 
Ø Venous sinus stenting 
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REVIEW OF LITERATURE 
Sandeep Randhawa and Gregory P.Van Stavern studied  
current standard of care in the diagnosis and treatment of idiopathic 
intracranial hypertension and concluded “that newer treatment modalities are 
being explored for IIH refractory to standard medical therapy, but their efficacy 
and safety must be demonstrated in large studies before they can be adopted as 
part of standard treatment”8. 
Martin G.Radvany et al described “ visual and neurological outcomes 
following Endovascular Stenting for Pseudotumor Cerebri  associated with 
Transverse sinus stenosis9”.  
D Soler et al described that “ the correct diagnosis of Benign 
Intracranial hypertension relies on the recognition of the typical symptoms, 
radiological exclusion of a mass lesion, and recognition of the possible 
diagnostic pitfalls”10. 
Ambika S et al described “the clinical profile, evaluation and 
management of idiopathic intracranial hypertension”1. 
Honorat R et al concluded that “ visual prognosis is generally better in 
children than in adults and no risk factors for visual sequelae were identified 11”. 
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Hannerz J and Ericson K studied “ The relationship between 
idiopathic intracranial hypertension and obesity”12. 
Wall M et al described the risk factors for poor visual outcome in 
patients with idiopathic intracranial hypertension13. 
Obi EE et al described that “ Optic nerve sheath fenestration is a safe 
procedure and predominantly stabilises visual function in majority of  
maximally medicated patients14”. 
Supuran CT studied and concluded that  “Acetazolamide is effective in 
the treatment of Idiopathic intracranial hypertension 15”. 
Mulla Y et al studied and concluded that “ Quality of life in IIH patients 
is significantly reduced and effective headache management is required to 
improve quality of life in IIH patients16”. 
Kanagalingam S and Subramanian PS described the  “role of Cerebral 
venous stenting in the management of patients with refractory pseudotumor 
cerebri17”. 
Elder BD et al described that venous stenting represents a viable 
treatment option for fulminant idiopathic intracranial hypertension 18. 
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Naarden MT described that patients with IIH are mainly overweight 
young women who present with raised intracranial pressure19. 
Ibrahim YA et al described the presence of Transverse dural venous 
attenuation on CT scans in 96% of patients with IIH and concluded that 
Venous attenuation sign is an additional imaging marker in the evaluation of  
IIH patients20. 
Wardly DE described “ Obstructive sleep apnoea as a potential risk 
factor for the development of Idiopathic intracranial hypertension” 21. 
Dave SB and Subramanian PS studied the treatment options for 
Pseudotumor cerebri  and concluded  “that weight reduction and medical 
management may be utilised for IIH cases without vision loss and surgical 
procedures for patients with severe vision loss”.22 
Banta JT and Farris BK described that “Optic nerve sheath 
decompression is a safe and effective means of stabilising visual acuity in 
patients with Pseudotumor cerebri with progressive visual loss despite maximal 
medical therapy”.23 
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Hingwala DR et al studied the imaging signs in patients with Idiopathic 
intracranial hypertension and concluded that Optic nerve head protrusion and 
globe flattening were associated with IIH24. 
Fridley J et al described that bariatric surgery may be an effective 
treatment for IIH in obese patients, both in terms of symptom resolution 
and visual outcome.25  
Valerie Biousse, Beau B. Bruce and Nancy J Newman studied the 
pathophysiology and management of IIH. They described that “ Vitamin A 
metabolism, adipose tissue and cerebral venous abnormalities are associated 
with IIH”26. 
Harvey J Sugerman et al described that gastric bariatric surgery was 
associated with resolution of  Pseudotumor cerebri in morbidly obese women 27. 
Susan P Mollan et al studied and concluded that “ IIH requires a 
multidisciplinary approach including ophthalmologists, neurologists and 
neurosurgeons. They also suggested that disease modifying therapy is weight 
loss and CSF shunting to be considered temporary”.28 
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John Chen described that “IIH is a disease of women in child-bearing 
years, and its prevalence is increasing due to the worldwide obesity 
epidemic”29. 
N.N.Baheti et al studied the long-term visual outcomes of IIH and 
concluded that “IIH patients can have delayed worsening or relapses and about 
one-tenth of patients have permanent visual loss early or late in the course of 
the disease”30. 
Bryan D.Riggeal et al studied the clinical course of IIH with Transverse 
sinus stenosis and described that transverse sinus stenosis is common in IIH 
and concluded that there is no correlation between the degree of Transverse 
sinus stenosis and the clinical course31. 
J.Alexander Fraser et al studied the risk factors for IIH in men and 
suggested a possible role of sex hormones and obstructive sleep apnoea in the 
pathogenesis of IIH in men32. 
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AIMS AND OBJECTIVES 
Ø To study the clinical profile of patients with idiopathic intracranial 
hypertension. 
Ø To study the behaviour and the natural course of idiopathic intracranial 
hypertension. 
Ø To study the neuroimaging features and to look for hypoplasia and 
stenoses of transverse and sigmoid sinuses. 
Ø To analyse the response to treatment and study the visual outcome. 
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MATERIALS AND METHODS 
STUDY DESIGN 
     Hospital based prospective study 
SOURCE OF DATA 
     Neuro ophthalmic services, Aravind Eye Hospitals 
STUDY SUBJECTS 
     Patients who were proven to have idiopathic intracranial hypertension 
both clinically and radiologically from December 2014 to May 2015 (6 
months) were enrolled for study. 
SAMPLE SIZE 
      61 Patients who were proven to have idiopathic intracranial hypertension 
clinically and radiologically from a period of December 2014 to May 2015 for 
a period of 6 months who presented to the Department of 
Neuroophthalmology,  Aravind Eye Hospital, Madurai. 
STUDY PERIOD 
      December 2014 to May 2015(6 months) 
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DATA ANALYSIS 
STATISTICAL METHODS 
 Mean (SD) or Frequency (Percentage) was used to describe summary 
information.  Statistical analysis was done by STATA 11.1 (Texas, USA). 
INCLUSION CRITERIA 
       It includes all patients with any of the following symptoms and signs with 
radiologically proven idiopathic intracranial hypertension 
Ø Signs and symptoms of idiopathic intracranial hypertension such as 
headache, transient obscuration of vision, defective vision, vomiting, 
neck pain, giddiness, field defects and diplopia. 
Ø No localising focal neurological signs except unilateral or bilateral sixth 
nerve paresis. 
Ø Normal neuroimaging results adequate to exclude cerebral venous 
thrombosis and intracranial tumours i.e magnetic resonance imaging of 
the brain, often with additional sequences (computed tomography or 
magnetic resonance venography) 
Ø Reproducible visual field defects. 
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EXCLUSION CRITERIA  
Ø Abnormalities on neurological examination aside from papilledema and 
its related visual loss or sixth nerve paresis. 
Ø Abnormal neuroimaging except for an empty sella, thickening of optic 
nerve sheath complex, stenoses of transverse and sigmoid sinuses and 
widening of peri-optic subarachnoid space. 
CLINICAL EVALUATION 
        A series of 61 patients who presented to our Neuro ophthalmology 
department with clinically and radiologically proven diagnosis of idiopathic 
intracranial hypertension were included in our study. All these patients 
underwent a thorough ophthalmological and neurological evaluation. 
        The patients’ particulars like name, age, sex, address were documented in 
a proforma specially designed for the study, and was filled by the examining 
doctor. 
        A detailed history of each and every symptom of the patient was taken 
such as the onset, duration, progression, associated factors, aggravating and 
relieving factors were documented. 
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       The patients were also enquired about the past medical and surgical 
history, systemic illness, treatment history, personal history and family history. 
EACH ONE OF THE PATIENT INCLUDED IN OUR STUDY HAS TO 
UNDERGO ROUTINE OPHTHALMIC EVALUATION 
§ Visual acuity by Snellen’s chart 
§ Refraction 
§ Pupillary reaction for normal pupil, sluggish pupil or RAPD. 
§ General ophthalmic examination with torch light and slit lamp 
biomicroscopy 
§ Intraocular pressure measurement by non-contact tonometry 
§ Fundus examination by direct ophthalmoscope and slit lamp 
biomicroscopy using 90 Dioptre lens and indirect ophthalmoscopy. 
§ Extraocular movement examination using torch light 
§ Colour vision evaluated by Pseudo-isochromatic Ishiharas chart 
§ Central fields by Bjerrums screen 
§ Visual fields by Automated perimetry (HFA 30-2) 
§ A complete neurological evaluation was done to every patient including 
general consciousness, cranial nerve examination, motor system 
evaluation and sensory system evaluation were done. 
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§ Neuroimaging was done in all patients either CT Brain or MRI/MRV 
with or without contrast depending upon the need and affordability of 
the individual patients. 
§ During follow up visual acuity, pupil reaction, colour vision, fields and 
fundus examination were done at one month and three months. 
§ Vitals such as pulse rate and blood pressure were recorded 
§ Weight, height and body mass index were done 
§ Systemic examination of cardiovascular, respiratory, central nervous 
system were done. 
§ Investigations such as haemoglobin percentage, random blood sugar, 
lipid profile and thyroid profile were done. 
§ Fundus photographs were taken for every patient 
§ During follow up weight, visual acuity, pupillary reaction, colour vision, 
central fields and fundus was done at one month and three months. 
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ANALYSIS AND RESULTS 
 
Analysis of collected data was done based on the following 
1. Incidence 
2. Age and sex distribution 
3. Presence or absence of various symptoms 
a. Yes-1 
b. No-2 
4. Duration of symptoms  
a. <1 month 
b. 1 month to 1 year 
c. > 1 year                            
5. Associated clinical features 
a. Yes-1 
b. No-2 
6. Presence of systemic illness 
a. Yes-1 
b. No-2 
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7. Past treatment history 
a. Yes-1 
b. No-2 
8. Personal history 
a. Yes-1 
b. No-2 
9. Body mass index 
a. Healthy 18.5 to 25 -1 
b. Overweight 25 to 30 -2 
c. Obese 30 to 35 -3 
d. Severely obese >35 -4 
10. Best corrected visual acuity 
a. 6/6 to 6/60 -1 
b. 5/60 to 1/60 -2 
c. <1/60 -3 
11. Intraocular pressure by non-contact tonometry 
12. Anterior segment examination 
13. Pupil examination 
a. Normal 
b. Sluggish 
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c. RAPD 
14. Colour vision by Ishihara’s chart 
a. Normal 
b. Defective 
15. Central fields by Bjerrums screen 
a. Normal 
b. Defective 
16. Fundus examination 
a. Early papilledema 
b. Established papilledema 
c. Chronic papilledema 
d. Resolving papilledema 
e. Optic atrophy 
17. Investigations-  
a. Random blood sugar 
b. Haemoglobin 
c. Fasting lipid profile 
d. Thyroid function test 
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18. Radiological findings 
a. Computed tomography 
b. Magnetic resonance imaging of brain 
c. Magnetic resonance venogram 
19. Fundus photography 
20. Visual fields by automated perimetry using Humphrey’s   Field 
Analyser(30-2) 
21. Treatment-Medical or Surgical 
22. Visual acuity at follow up- Static/Improved/Worsened 
23. Fundus status at follow up 
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AGE 
 Mean (SD) of the age is 29.97(8.41) years and it ranges from 16 years to 
49 years 
GENDER 
Gender n % 
Male 5 8.2 
Female 56 91.8 
Total 61 100 
 
DEFECTIVE VISION 
Defective vision n % 
Yes 18 29.5 
No 43 70.5 
Total 61 100 
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DURATION OF DEFECTIVE VISION 
Duration of defective vision n % 
<1month 11 61.1 
1month – 1 year 7 38.9 
Total 18 100 
 
Complaints n(%) 
Headache 54(88.5) 
Transient Obscuration of Vision 25(41.0) 
Field defects 1(1.6) 
vomiting 23(37.7) 
Diplopia 9(14.8) 
Neck pain 14(22.9) 
Giddiness 5(8.2) 
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SYSTEMIC DISEASE 
Systemic Disease n % 
Diabetes/ Hypertension/ Thyroid 1 1.6 
Hypertension 3 4.9 
Hypertension/ Dyslipidemia/ PCOD 1 1.6 
Hypothyroid 3 4.9 
Pregnancy induced  
Hypertension/ PCOD 
1 1.6 
Nil 52 85.3 
Total 61 100 
 
TREATMENT HISTORY 
Treatment History n % 
Anti-DM/ Anti-HT/ Thyroxine 1 1.6 
Anti-HT 3 4.9 
Anti-HT/ OCP 1 1.6 
Doxy/ Vit A 1 1.6 
OCP 1 1.6 
Thyroxine 3 4.9 
Nil 51 83.6 
Total 61 100 
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VITALS 
Vitals Mean(SD) Min – Max 
Weight 67.59(12.98) 47 – 100 
Height 151.98(6.16) 140 – 177 
IOP 14.25(2.27) 10 – 20 
Blood Pressure 
     Systolic BP 
     Diastolic BP 
 
119.90(15.73) 
77.77(11.48) 
 
90 – 160 
50 - 120 
 
WEIGHT 
Weight Mean(SD) Min – Max 
Visit1 67.59(12.98) 47 – 100 
Visit2 66.35(12.55) 47 – 98 
Visit3 66.44(12.91) 50 – 98 
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BODY MASS INDEX 
BMI n % 
Healthy 14 23.0 
Overweight 29 47.5 
Obese 11 18.0 
Severely Obese 7 11.5 
Total 61 100 
 
OCULAR EXAMINATION 
BCVA 
BCVA(n=122) Visit1 Visit2 Visit3 Final 
6/6 – 6/60  121(99.18) 113(100.0) 86(100.0) 113(100.0) 
5/60 – 1/60 - - - - 
<1/60 1(0.8) - - - 
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PUPIL 
Pupil(n=122) Visit1 Visit2 Visit3 Final 
Normal 104(85.2) 106(93.0) 86(100.0) 110(96.5) 
Sluggish 16(13.1) 7(6.1) - 3(2.6) 
RAPD 2(1.6) 1(0.9) - 1(0.9) 
 
EOM 
EOM n % 
Normal 113 92.6 
Abnormal (6th nerve paresis  9 7.4 
Total 122 100 
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FUNDUS 
Fundus(n=122) Visit1 Visit2 Visit3 Final 
Early 
Papilledema 
52(42.6) 4(3.5) - - 
Established 
Papilledema 
66(54.1) 24(21.1) 2(2.3) 4(3.5) 
Chronic 
Papilledema 
4(3.3) 5(4.4) 2(2.3) 4(3.5) 
Chronic 
papilledema and 
Optic atrophy 
- 2(1.8) - 2(1.7) 
Normal - 10(8.8) 46(53.5) 56(49.1) 
Resolving 
papilledema 
- 69(60.5) 36(41.9) 48(42.1) 
 
COLOR VISION 
Color Vision Visit1 Visit2 Visit3 Final 
Normal 115(94.3) 110(98.2) 74(100.0) 110(98.2) 
Defective 7(5.7) 2(1.8) - 2(1.8) 
 
 
93 
 
CENTRAL FIELDS 
Central Fields Visit1 Visit2 Visit3 Final 
Normal 104(85.2) 106(94.6) 71(97.3) 108(96.4) 
Defective 18(14.8) 6(5.4) 2(2.7) 4(3.6) 
 
INVESTIGATIONS 
Investigations Normal Abnormal 
Hemoglobin 34(55.7) 27(44.3) 
RBS 61(100) - 
Lipid profile 56(93.3) 4(6.7) 
TFT 55(90.2) 6(9.8) 
HFA 30-2 30(49.2) 31(50.8) 
 
CT BRAIN 
CT Brain n % 
1 8 66.7 
1 and 2 4 33.3 
Total 12 100 
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MRI 
MRI n % 
1 19 35.9 
1 and 2 34 64.1 
Total 53 100 
 
CT Brain/ MRI n % 
CT Brain 8 13.1 
MRI 53 86.9 
Total 61 100 
 
CT / MRI - Final n % 
1 23 37.7 
1 and 2 38 62.3 
Total 61 100 
 
MRV 
MRV n % 
B/L TSS 1 1.9 
HLTS/ HLSS 16 30.2 
HLTS/ HLSS/ RTS/ RSS 2 3.8 
HRTS/ HRSS/ LTS 1 1.9 
LTS 1 1.9 
LTS/ LSS 1 1.9 
RTS 1 1.9 
Normal 30 56.6 
Total 53 100 
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TREATMENT 
Treatment Visit1(n=61) Visit2(n=55) Visit3(n=34) Final 
DMX 13(21.3) 12(21.8) 5(14.7) 11(20.0) 
DMX, IS 5(8.2) 2(3.6) 1(2.9) 1(1.8) 
DMX, WR 24(39.3) 23(41.8) 7(20.6) 16(29.1) 
DMX, WR, IS 15(24.6) 11(20.0) 9(26.5) 12(21.8) 
LP 1(1.6) - - - 
MANNITOL 1(1.6) 1(1.8) - - 
ONSD 2(3.3) - - - 
TOPIRAL - 2(3.6) 1(2.9) 1(1.8) 
TOPIRAL, 
WR 
- 1(1.8) - - 
WR - 2(3.6) 8(23.5) 10(18.2) 
WR, IS - 1(1.8) 1(2.9) 2(3.6) 
IS - - 2(5.9) 2(3.6) 
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DISCUSSION 
   Idiopathic intracranial hypertension can present with varied clinical 
symptoms, neuro-ophthalmic features and radiological features. It is a disorder 
of elevated cerebrospinal fluid pressure of unknown cause that usually occurs 
in obese women in the childbearing years. 
           In our prospective study we included 61 patients. The mean age group is 
29.97 years which ranges between 16 years to 49 years. This mean age is 
younger than that recorded as 32.89 years in a study conducted  by Ambika S 
et al in a tertiary referral ophthalmic centre in India 1 and almost equal to the 
age in another study which was conducted in North America in which it was 
29.0 years2 
               In our study, out of 61 patients 56(91.8%) were females and 5(8.2%) 
were males which is almost equal to the retrospective study conducted in a 
tertiary ophthalmic centre in India1. John Chen and Michael Wall found that 
female gender is an obvious risk factor for IIH since 90% of the affected 
population were obese females.29 
              The most common complaints in our study patients were 
headache(88.5%), transient obscuration of vision(41.0%), vomiting(37.7%), 
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defective vision(29.5%), neck pain(22.9%), diplopia(14.8%), giddiness(8.2%) 
and field defect(1.6%). The most common complaint is headache(88.5%) in 
our study group which is more than the study conducted in India1 which was 
76%. Most of our patients presented within one month of duration. 
         Among our study patients, 9 patients (14.7%) had systemic illness history 
such diabetes, hypertension, dyslipidemia, pregnancy induced hypertension and 
polycystic ovarian disease. Remaining 52 patients (85.3%) had no systemic 
illness. Inbal Avisor Et Al reported the association of PCOD and IIH.33 
          In our study, 2 patients gave history of treatment with oral contraceptive 
pills for menstrual irregularities, 1 patient took treatment for acne with oral 
doxycycline and vitamin A capsules and 3 patients had treatment history with 
thyroxine for hypothyroidism. John Chen and Michael Wall in a study 
reported that vitamin A intoxication and other forms of Vitamin A such as 
Isotretinoin given for the treatment of acne are also associated with IIH 29 
           The body mass index was calculated as weight in kilograms divided by 
height in meters squared in our study and 47.5% were overweight, 23% were 
healthy, 18% were obese and 11.5% were severely obese. Daniels AB Et Al 
found that higher BMIs were associated with greater risk of IIH.5 Aimee J. 
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Szewka Et Al did a retrospective study and reported that higher BMI at 
diagnosis is associated with increased severe visual loss in patients with IIH. 35 
            On presentation, Best corrected visual acuity was found to range from 
6/6 to Hand movements in our study population. Out of 122 eyes, 121 eyes had 
visual acuity between 6/6 to 6/60 and one eye had visual acuity of hand 
movements on presentation. In a retrospective study in India1 , 55 eyes had 
visual acuity of 6/6, 20 eyes had visual acuity between 6/9 to 6/18, 7 eyes had 
visual acuity between 6/24 to 6/60 and 18 eyes had <6/60. 
           In our study,  Pupillary examination was normal in 104 eyes(85.2%), 
sluggish in 16 eyes(13.1%) and Relative Afferent Pupillary defect in 2 
eyes(1.6%). 
           Extraocular movements were normal in 92.6% and abnormal in 7.4%.  
Most common involvement in our study group was the sixth nerve. Horizontal 
diplopia was reported due to sixth nerve paresis which is a false localising sign 
in IIH. In a study by Michael Wall, he reported horizontal diplopia in 1/3 rd of 
IIH patients and sixth nerve paresis were found in 10 to 20% of cases. 29 
                  Fundus examination of our patients showed early papilledema in 52 
eyes(42.6%), established papilledema in 66 eyes(54.1%) and chronic 
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papilledema in 4 eyes(3.3%). One patient progressed to optic atrophy as a 
result of chronic papilledema. Papilledema is the most common sign and is 
usually symmetric, but can be highly asymmetric or unilateral in 10% of 
patients36. In our study, papilledema was bilateral in 59 patients but asymmetric 
in 2 patients with one eye early papilledema and one eye established 
papilledema. 
          In our study, Colour vision was defective in 7 eyes(5.7%) and normal in 
115 eyes(94.3%). In retrospective study in India, colour vision analysis showed 
that colour vision was normal in 16 patients and affected in 10 patients. 1 
           Central fields were normal in 104 patients(85.2%) and defective in 18 
patients(14.8%) in our study population. Most common defect was an enlarged 
blind spot in the affected patients. 
            In our study, blood investigations such as haemoglobin, random blood 
sugar, fasting lipid profile and fasting thyroid profile were done for all the 
patients. Haemoglobin values were normal in 34 patients(55.7%) and below 
normal in 27 patients(44.3%). Random blood sugar values were normal in all 
the patients(100%). Lipid profile was normal in 56 patients(93.3%) and 
abnormal in 4 patients(6.7%). Thyroid profile was normal in 55 
patients(90.2%) and altered in 6 patients(9.8%).  
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             Our study highlights the possible association between iron deficiency 
anemia and IIH evidenced by resolution of papilledema after correction of iron 
deficiency. Bhavna Et Al studied iron deficiency masquerading as idiopathic 
intracranial hypertension in a 13 year old girl.37 
In our study, 6 patients were hypothyroid and 4 were on thyroxine  
replacement therapy. Ester Coutinho Et Al reported Grave’s disease as a rare 
cause of Pseudotumor cerebri38. Thyroid disturbances in the form of 
hypothyroidism, hyperthyroidism and thyroxine replacement therapy have 
unique correlation with this disorder.  
Automated perimetry was done by Humphrey’s Field analysis 30-2 to 
assess visual field loss in our study. Fields were normal in 30 patients(49.2%) 
and abnormal in 31 patients(50.8%). Most common defects were enlarged 
blind spot and generalised constriction of fields. In a retrospective study 
conducted in India, the most common visual field defect was an enlarged blind 
spot which was noted in 60 eyes and other field defects were advanced 
generalised constricted fields as well as nasal and arcuate defects in seven 
eyes.1 In a prospective study conducted by Michael Wall, the most common 
defects were enlargement of physiologic blind spot and loss of inferonasal 
portions of the visual field along with constriction of isopters.13  
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Neuroimaging was done in all our patients (Computed tomography of 
brain and Magnetic Resonance Imaging with Magnetic Resonance 
Venography). Patients who were not affordable for MRI and MRV underwent 
imaging by Computed tomography. 53 patients underwent neuroimaging by 
MRI and MRV. Eight  Patients underwent neuroimaging by CT. 
In neuroimaging, 38 Patients showed both thickening of optic nerve 
sheath with widening of perioptic subarachnoid space and partial empty sella. 
23 patients showed only thickening of optic nerve sheath with widening of 
perioptic subarachnoid space alone. 
Out of the 53 patients who underwent MRI and MRV, 23 patients had 
either congenital hypoplasia or stenosis of transverse sinus or sigmoid sinus or 
both. In the other 30 patients, MRV was normal without stenoses or 
hypoplasia. There was no evidence of venous thrombosis in any of our patients 
ruling out cerebral venous thrombosis.    
Out of our 23 patients, 16 (30.2%) had hypoplasia of left transverse 
sinus stenosis and hypoplasia of left sigmoid sinus stenosis, 2 patients had 
hypoplasia of both left transverse and left sigmoid sinus stenoses with right 
transverse sinus and right sigmoid sinus stenoses, 1patient had bilateral 
transverse sinus stenoses, 1 patient had hypoplasia of both right transverse and 
102 
 
right sigmoid sinuses with left transverse sinus stenosis, 1 patient had left 
transverse sinus stenosis alone, 1 patient had right transverse sinus stenosis 
alone and 1 patient had  both left transverse and sigmoid sinus stenoses. 
 In a retrospective study done in 20 patients with Pseudotumor cerebri by 
Brodsky MC and Vaphiades M, the MRI disclosed flattening of posterior 
sclera in 80%, empty sella in 70%, distension of the perioptic subarachnoid 
space in 45%, enhancement of the prelaminar optic nerve in 50%, vertical 
tortuosity of the orbital optic nerve in 40% and intraocular protrusion of the 
prelaminar optic nerve in 30%39 
 M Neil Et Al studied the presence of bilateral transverse sinus stenosis 
causing idiopathic intracranial hypertension in a 19 years old man and 
suggested that a defective sinus venous drainage is primarily responsible for 
IIH40 
Out of the 61 patients, 24 with high BMI were treated with Diamox 
tablets (Acetozolamide 250mg BD) and were advised Weight reduction, 15 
patients who had coexisting Anaemia and with high BMI were treated with 
Diamox tablets and iron supplements along with Weight reduction, 13 whose 
BMI was normal were treated with Diamox alone, 1 patient underwent lumbar 
puncture for both diagnostic and therapeutic purposes, one patient was initially 
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treated with intravenous Mannitol and maintained with Diamox in the 
subsequent follow ups and 2 patients underwent surgical          decompression 
by unilateral Optic Nerve Sheath Decompression. Two patients developed 
intolerance to Diamox and were treated with Topiramate tablets (Topiral).  
. Weight reduction should be recommended for all obese and overweight 
IIH patients. Weight control improves the overall quality of life. Carbonic 
anhydrase inhibitors like acetazolamide 1gm daily or 250mg QID and 
methazolamide are the main medical treatment classically prescribed for IIH. 26 
They decrease CSF production by inhibiting carbonic anhydrase in the 
choroidal plexus and also by mild dieresis. Side effects include lethargy, 
paraesthesia and altered taste sensation.22 
Topiramate is a sulfa-derivative monosaccharide which acts by blockage 
of voltage gated sodium channels. It is mainly licensed for treatment of 
epilepsy and migraine prophylaxis. It is also an anti-obesity agent.  
Symptoms of raised ICT and papilledema improve with treatment of 
anaemia. The mechanism is mainly by increased cerebral blood flow that 
maintains cerebral oxygen delivery.16 
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Mannitol is the most commonly used hyperosmolar agent for the 
treatment of IIH.16It has both rheologic and osmotic effects. It causes reduction 
in hematocrit and in blood viscosity, thereby increasing cerebral blood flow 
and increase in oxygen delivery.42 
Lumbar puncture is most commonly done for evaluation of an acute 
headache and to rule out inflammatory or infective conditions of nervous 
system. The treatment of raised Intracranial pressure itself begins with 
diagnostic lumbar puncture which is often effective in relieving the symptoms 
and signs.26 
Optic nerve sheath fenestration is done mainly for visual symptoms. It 
has also been proven recently to improve headaches. It is an effective long-
term procedure for visual loss in IIH.43 In ONSF, the dural sheath surrounding 
the retrolaminar portion of the optic nerve is fenestrated which creates a fistula 
between the subarachnoid space and orbital cavity. Finally, there is a reduction 
in the pressure around the nerve leading to resolution of papilledema and 
improvement of visual symptoms. 
Transverse sinus stenoses is a common finding in IIH. It has been 
proposed that external compression of the venous sinus due to raised ICP 
results in stenoses. Stenting of the stenoses may reduce cerebral venous 
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pressure43 Mohamed S Teleb Et Al did a study on systematic analysis of 
Transverse sinus stenting in IIH.44 Endovascular stenting for dural venous 
stenosis is a safe and feasible procedure.  
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CONCLUSION 
     Idiopathic intracranial hypertension is characterized by elevated CSF 
pressure without apparent cause. Obese women of child-bearing age are more 
commonly involved than males. Most common complaint was headache in our 
study patients. Most of our patients presented within one month duration. 
Commonly associated risk factors are thyroid dysfunction, anemia, pregnancy, 
hypertension, exposure to exogenous drugs like tetracyclines, oral 
contraceptives, vitamin A supplements and thyroid replacement therapy. 
Anemia was a significant risk factor in our study population. High body mass 
index and recent weight gain is associated with IIH. Visual acuity was 6/6 in 
most eyes in our study.  Sixth nerve paresis occurs as a false localizing sign in 
IIH. Most of the patients presented with established papilledema.  Most 
common visual field defect is an enlarged blind spot in both Central fields test 
by Bjerrums Screen and Automated perimetry. In MRI and CT brain, 
thickening of optic nerve sheath and empty sella were the most common 
findings in our patients. In MRV study, 30.2%(16) patients had hypoplasia of 
left transverse sinus stenosis and hypoplasia of left sigmoid sinus stenosis. 
Patients who had high BMI were treated with Acetazolamide 250mg BD with 
Weight reduction. Patients who had coexisting Anaemia were treated with iron 
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supplements along with acetazolamide. One patient was treated by lumbar 
puncture and two patients were treated with unilateral Optic Nerve Sheath 
Fenestration. Follow up at one month and at three months showed resolving 
papilledema in most cases. 
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LIMITATIONS 
1. Few patients who were not affordable for MRI/MRV underwent CT study. 
2. Few patients were lost for follow up. 
3. Lack of a comparison group limiting our ability to assess the degree of 
stenosis typical of normal individuals. 
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PROFORMA-IDIOPATHIC INTRACRANIAL 
HYPERTENSION 
 
      CASE NO                                 - 
      DATE 
      M.R.NO 
      NAME 
      AGE/SEX 
      OCCUPATION 
       PLACE 
COMPLAINTS 
   HEADACHE                    -YES / NO                                                                
COMPLAINTS 
    TRANSIENT OBSCURATION OF VISION – YES / NO                                  1- YES 
   DEFEECTIVE VISION     -  DURATION                                                            2- NO 
                                             -  UNILATERAL / BILATERAL                             
DURATION 
                                             -  SUDDEN / INSIDIOUS                                    1- < 1 
MONTH 
                                             -  PAINFUL / PAINLESS                                     2- 1 MONTH 
TO 1 YEAR 
                                             -  PROGRESSIVE / STATIONARY                     3- > 1 
YEAR 
  FIELD DEFECTS                - YES / NO 
  VOMITING                       - YES / NO 
  DIPLOPIA                          - YES / NO 
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  NECK PAIN                       - YES / NO 
  GIDDINESS                       - YES / NO 
 
PAST HISTORY                                                                   PAST 
H/O 
     DIABETES                     - YES / NO                                                          1- YES     2- 
NO 
      HYPERTENSION          - YES / NO                                              DIABETES-DM                
       DYSLIPIDEMIA            - YES / NO                                             HYPERTENSION-
HT 
       CARDIAC ILLNESS       - YES / NO                                            HYPOTHYROID 
BRONCHIAL ASTHMA- YES / NO                              PCOD-POLYCYSTIC 
OVARIAN DISEASE 
MIGRAINE                    - YES / NO                                           DYSLIPIDEMIA-
DYSLIP 
       THYROID DISEASE      - YES / NO                      PIH-PREGNANCY 
INDUCED HYPERTENSION 
TREATMENT HISTORY                                         TREATMENT 
H/O 
       ANTI-DIABETIC                                                                           1- YES   2- NO 
       ANTI-HYPERTENSIVE 
       THYROID DRUGS 
       CARDIAC DRUGS 
       HYPERLIPIDEMIA 
       ORAL CONTRACEPTIVES (OCP) 
       VITAMIN A SUPPLEMENTS 
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PERSONAL HISTORY                                               PERSONAL 
H/O 
       SMOKER                              - YES / NO                                         1- YES   2- NO 
       ALCOHOLIC                         - YES / NO 
       SNORING                             - YES / NO 
       DIET                                      - VEG / NON-VEG 
 
FAMILY HISTORY                                                       FAMILY 
H/O 
1- YES    2-NO 
 
VITALS 
         PULSE RATE 
         BLOOD PRESSURE (BP) 
         BODY WEIGHT (KG) 
         HEIGHT (CM)                                                    
        BODY MASS INDEX (BMI)                             BMI= Weight 
(kg)/height^2(metres) 
         CVS                                              1-HEALTHY 18.5 TO 25 
         RS                                                   2-OVERWEIGHT 25 TO 30 
         CNS                                     3-OBESE 30 TO 35 
         ABDOMEN                                              4-SEVERELY OBESE >35 
OCULAR EXAMINATION      
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                                                             RE                                       LE 
       BCVA                                                                                                                                               
BCVA  
       IOP                                                                                                                                 1- 
6/6 TO 6/60 
       ANTERIOR SEGMENT        2- 5/60 TO 
1/60 
      PUPIL        3- <1/60 
             NORMAL / SLUGGISH / RAPD   PUPIL 
       COLOUR VISION (CV) 1- 
NORMAL 
       CENTRAL FIELDS (CF) 2-
SLUGGISH 
       FUNDUS 3- RAPD 
             DISC EDEMA CV  and  
CF 
             BLURRING OF DISC MARGIN                                                             1- 
NORMAL  2-DEFECTIVE 
             DISC HYPEREMIA                                                                     EP- EARLY 
PAPILLEDEMA 
             SPLINTER HEMORRHAGES                                                 ESP- 
ESTABLISHED PAPILLEDEMA 
             MACULAR EDEMA CP- CHRONIC 
PAPILLEDEMA 
             PATON’S LINES 
             DILATED TORTUOUS VESSELS 
             HARD EXUDATES 
                    MACULAR FAN / STAR 
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             BACKGROUND RETINA 
             OTHERS 
INVESTIGATIONS                                                            
INVESTIGATIONS    
             HEMOGLOBIN 1- NORMAL 
             BLOOD GLUCOSE 2-ABNORMAL 
             LIPID PROFILE CT SCAN 
             THYROID PROFILE                                                      1-THICKENING OF 
OPTIC NERVE 
             CT SCAN                                                                              SHEATH WITH 
WIDENING OF 
             MRI AND MRV                                                          PERIOPTIC 
SUBARACHNOID SPACE 
             FUNDUS PHOTO 2- PARTIAL EMPTY SELLA 
 MRI 
              HFA  30-2 1- THICKENING OF OPTIC 
NERVE 
TREATMENT SHEATH WITH WIDENING 
OF 
                                                                          PERIOPTIC 
SUBARACHNOID SPACE 
                                                                                                2-PARTIAL EMPTY SELLA 
 
       MRV 
             HLTS- HYPOPLASIA OF LEFT TRANSVERSE SINUS 
                 HLSS- HYPOPLASIA OF LEFT SIGMOID SINUS 
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                  LTS-LEFT TRANSVERSE SINUS STENOSIS   
                  LSS- LEFT SIGMOID SINUS STENOSIS  
                 RTS- RIGHT TRANSVERSE SINUS STENOSIS 
                 RSS- RIGHT SIGMOID SINUS STENOSIS 
HFA 30-2               1- NORMAL              2-ABNORMAL 
 
    TREATMENT         DMX- DIAMOX   
                                   WR- WEIGHT REDUCTION 
 IS- IRON SUPPLEMENTS 
 LP-LUMBAR PUNCTURE 
                                        ONSD- OPTIC NERVE SHEATH DECOMPRESSION 
                                   
                                          FOLLOW UP AT 1 MONTH 
WEIGHT 
HEIGHT 
BMI 
BLOOD PRESSURE 
OCULAR EXAMINATION 
                                                                RE                                         
LE 
BCVA 
IOP 
ANTERIOR SEGMENT 
PUPIL 
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               NORMAL / SLUGGISH / RAPD 
COLOUR VISION 
CENTRAL FIELDS 
FUNDUS 
              DISC EDEMA 
              BLURRING OF DISC MARGINS 
              DISC HYPEREMIA 
              SPLINTER HEMORRHAGES 
              MACULAR EDEMA 
              PATON’S LINES 
              DILATED TORTUOUS VESSELS 
              HARD EXUDATES 
                    MACULAR FAN / STAR 
              BACKGROUND RETINA 
              OTHERS 
INVESTIGATIONS 
           FUNDUS PHOTO 
                                   
FOLLOW UP AT 3 MONTHS 
WEIGHT 
HEIGHT 
BMI 
OCULAR EXAMINATION 
                                                  RE                                              LE 
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BCVA 
IOP 
ANTERIOR SEGMENT 
PUPIL 
                  NORMAL / SLUGGISH / RAPD 
COLOUR VISION 
CENTRAL FIELDS 
FUNDUS 
              DISC EDEMA 
              BLURRING OF DISC MARGINS 
              DISC HYPEREMIA 
              SPLINTER HEMORRHAGES 
              MACULAR EDEMA 
              PATON’S LINES 
              DILATED TORTUOUS VESSELS 
              HARD EXUDATES 
                        MACULAR FAN / STAR 
              BACKGROUND RETINA 
              OTHERS 
INVESTIGATIONS 
   FUNDUS PHOTO 
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ABBREVIATIONS 
BCVA              -      Best Corrected Visual Acuity 
RAPD              -       Relative Afferent Pupillary Defect 
CT                    -       Computed Tomography 
MRI                 -        Magnetic Resonance Imaging 
MRV               -         Magnetic Resonance Venography 
ONSD              -        Optic Nerve Sheath Decompression 
ICP                   -        Intra Cranial Pressure 
IIH                   -        Idiopathic Intracranial Hypertension 
BMI                 -         Body Mass Index 
CSF                 -          Cerebrospinal Fluid 
ONSF              -          Optic Nerve Sheath Fenestration 
ONH              -            Optic Nerve Head 
ICT                 -            Intracranial Tension 
MRA               -          Magnetic Resonance Angiography 
IOP                 -            Intraocular Pressure 
HFA               -             Humphrey’s Field Analyser 
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KEY TO MASTER CHART 
DOV               -          Date of Visit 
TOV               -           Transient Obscuration of Vision 
EOM              -            Extraocular Movements 
BCVA            -            Best Corrected Visual Acuity 
IOP                -            Intraocular Pressure 
BP                  -            Blood pressure 
V/A              -               Visual Acuity 
CV                 -             Colour Vision 
CF                 -              Central Fields 
TFT               -              Thyroid Function Tests 
FUNDUS 
EP                -              Early Papilledema 
ESP              -              Established Papilledema 
CP                -              Chronic Papilledema 
RP                -              Resolving Papilledema 
OA               -               Optic Atrophy 
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N                  -                Normal 
 
CT AND MRI/MRV 
LTS                    -               Left Transverse Sinus Stenosis 
RTS                   -                Right Transverse Sinus Stenosis 
LSS -                Left Sigmoid Sinus Stenosis 
HLTS - Hypoplasia of Left Transverse Sinus 
HLSS        -         Hypoplasia of Left Sigmoid Sinus  
HRSS - Hypoplasia of Right Sigmoid Sinus 
TSS                  -                  Transverse Sinus Stenosis 
TREATMENT 
DMX                 -                 Diamox 
WR                    -                 Weight Reduction 
IS                       -                  Iron Supplements 
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1 Theen banu 24 F 393-0778 02.12.2014 2 1 1 2 2 2 1 2 HT, DYSLIP, PCODAnti-HT, OCPNIL 100 158 4 160/120 1 1 1 1 1 1 EP EP 16 17 1 1 1 1 1 1 2 1
2 Prasanna 30 F 394-0142 15.12.2014 1 2 1 2 2 2 2 2 2 NIL NIL NIL 75 148 3 130/80 1 3 1 3 1 1 CP CP 12 12 2 2 2 2 1 1 1 1
3 Singammal 25 F 151-4926 16.12.2014 2 1 1 2 2 2 1 2 NIL NIL NIL 56 140 2 110/70 1 1 1 1 1 1 EP EP 17 16 1 1 1 1 2 1 1 1
4 Gnana vennila 22 F 394-2588 17.12.2014 2 1 2 2 1 1 1 2 NIL NIL NIL 52 146 1 110/70 1 1 1 1 2 1 EP EP 15 12 1 1 1 1 1 1 1 1
5 Yuvanika 19 F 394-2776 18.12.2014 1 1 1 1 2 1 2 2 2 NIL DOXY, VIT ANIL 47 150 1 120/80 1 1 1 1 1 1 ESP ESP 14 12 1 1 1 1 1 1 1 1
6 Vanitha 18 F 394-5956 23.12.2014 1 1 2 2 2 1 2 1 2 NIL NIL NIL 50 150 1 90/60 1 1 1 1 2 1 ESP ESP 16 13 1 1 1 1 2 1 1 1
7 Sabeera barvin 29 F 392-4144 25.12.2014 2 1 1 2 2 2 2 2 PIH, PCOD OCP NIL 60 151 2 120/80 1 1 1 1 1 1 EP EP 18 15 1 1 1 1 1 1 1 1
8 Pavithra 19 F 394-8265 26.12.2014 1 2 1 1 2 2 2 2 2 NIL NIL NIL 60 162 1 100/80 1 1 1 1 1 1 EP EP 14 15 1 1 1 1 1 1 1 1
9 Joselin amala 21 F 395-0433 29.12.2014 2 1 2 2 2 2 2 2 NIL NIL NIL 55 153 1 110/70 1 1 1 1 1 1 EP EP 12 12 1 1 1 1 2 1 1 1
10 Senthil kumar 32 M 360-8608 07.01.2015 2 1 2 2 1 2 2 2 NIL NIL NIL 65 158 2 110/70 1 1 1 1 1 1 EP EP 11 14 1 1 1 1 1 1 1 1
11 Ruth renuga 34 F 395-8323 12.01.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 76 156 3 140/90 1 1 1 1 1 1 EP EP 15 15 1 1 1 1 1 1 1
12 Chitra 35 M 395-8713 13.01.2015 2 1 2 2 1 2 1 1 NIL NIL NIL 51 148.5 1 110/80 1 1 1 1 1 1 EP EP 16 14 1 1 1 1 1 1 1 1
13 Ravi 29 M 396-0210 16.01.2015 1 1 1 2 2 1 1 1 2 NIL NIL NIL 54 145 2 120/90 1 1 1 1 1 2 EP EP 16 14 1 1 1 1 1 1 1 1
14 Podhu ponnu 31 F 149-3398 19.01.2015 1 2 1 2 2 1 2 2 2 NIL NIL NIL 62 150 2 90/50 1 1 3 1 1 1 ESP ESP 12 12 2 2 1 1 2 1 1 2
15 Annapoorani 24 F 396-3453 22.01.2015 2 2 1 2 2 2 2 2 NIL NIL NIL 73 145 3 130/70 1 1 1 1 1 1 ESP EP 10 13 1 1 1 1 1 1 1 1
16 Jamila banu 35 F 357-2883 24.01.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 69 152 3 120/80 1 1 1 1 1 1 EP EP 17 16 1 1 1 1 2 1 2 1
17 Jeyalakshmi.A 49 F 396-4860 24.01.2015 2 1 1 2 2 2 2 2 NIL NIL NIL 70 155 2 100/70 1 1 1 1 1 1 ESP ESP 12 13 2 1 2 1 1 1 1 1
18 Chinnanthi 36 F 396-5380 26.01.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 86 153 4 130/90 1 1 1 1 1 1 EP EP 14 18 1 1 1 1 1 1 1 1
19 Uma maheswari 45 F 396-6047 26.01.2015 1 2 1 2 2 1 2 2 1 NIL NIL NIL 68 151 2 128/80 1 1 1 1 1 1 EP EP 14 18 1 1 1 1 2 1 1 1
20 Emimal  florance 37 F 396-5606 26.01.2015 2 1 1 2 2 2 2 2 NIL NIL NIL 54 152 1 100/60 1 1 1 1 1 1 ESP ESP 11 14 1 1 1 1 2 1 1 1
21 Meher nisha 30 F 377-9916 27.01.2015 1 2 2 1 2 2 2 2 2 NIL NIL NIL 83 153 4 120/80 1 1 1 1 1 1 ESP ESP 15 15 1 1 1 1 2 1 1 2
22 Jayalakshmi.M 43 F 396-9019 31.01.2015 2 1 1 2 2 2 2 2 DM,HT,THYROIDAnti-DM,Anti-HT,ThyroxineNIL 66 154 2 150/90 1 1 1 1 1 1 ESP ESP 15 14 1 1 1 1 2 1 2 1
23 Valarmathi 36 F 397-0511 03.02.2015 1 1 2 2 2 2 2 2 2 HT Anti-HT NIL 55 149 1 110/70 1 1 1 2 1 1 ESP ESP 16 16 1 1 1 1 2 1 1 1
24 Saraswathi 34 F 397-1704 04.02.2015 2 1 1 2 2 2 2 2 NIL NIL NIL 70 150 3 130/80 1 1 1 1 1 1 EP EP 12 12 1 1 1 1 2 1 1 1
25 Gayathri 29 F 397-2146 05.02.2015 2 1 2 2 1 2 2 2 NIL NIL NIL 71 155 2 110/80 1 1 1 1 1 1 ESP ESP 15 14 1 1 2 2 1 1 1 1
26 Saranya 17 F 397-2113 05.02.2015 2 1 2 2 1 2 1 2 NIL NIL NIL 64 148.5 2 100/60 1 1 1 1 1 1 EP EP 12 14 1 1 1 1 1 1 1 1
27 Bharathi priya 21 F 397-4634 09.02.2015 2 1 1 2 1 2 1 1 NIL NIL NIL 50 145.5 1 110/80 1 1 1 1 1 1 ESP ESP 10 12 1 1 1 1 2 1 1 1
28 Bashurun  32 F 397-4728 10.02.2015 2 1 1 2 1 2 2 2 NIL NIL NIL 84 158.5 3 110/70 1 1 1 1 1 1 ESP ESP 12 12 1 1 2 2 1 1 1 2
29 Vaishnavi 16 F 397-7805 14.02.2015 2 2 1 1 2 1 1 1 2 NIL NIL NIL 70 149 3 100/60 1 1 1 1 1 1 EP EP 15 12 1 1 1 1 2 1 1 1
30 Bharathi 28 F 379-5064 14.02.2015 1 1 1 2 2 2 2 2 NIL NIL NIL 65 149 2 120/80 1 1 1 1 1 1 EP EP 15 14 1 1 1 1 2 1 1 1
31 Uma 17 F 398-0827 18.02.2015 1 1 2 2 1 2 2 2 NIL NIL NIL 64 151 2 110/70 1 1 1 1 1 1 ESP ESP 15 14 1 1 1 1 1 1 1 1
32 Murugalakshmi 26 F 398-4407 24.02.2015 2 1 1 2 2 1 2 2 NIL NIL NIL 62 143 3 120/80 1 1 1 1 1 2 ESP ESP 15 13 1 1 1 1 1 1 1 1
33 Guruvammal 45 F 398-4800 25.02.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 61 150.5 2 140/80 1 1 1 1 1 1 CP CP 18 19 1 1 1 1 2 1 1 1
34 Pandiarajan 41 M 398-5842 26.02.2015 2 1 1 2 2 2 2 2 HT Anti-HT NIL 90 170.5 3 140/100 1 1 1 1 1 1 EP EP 15 15 1 1 1 1 2 1 1 1
35 Rajeshwari 24 F 398-9194 03.03.2015 1 1 1 1 2 2 2 2 2 NIL NIL NIL 68 154 2 120/60 1 1 2 2 1 1 ESP ESP 14 16 1 1 1 1 2 1 1 1
36 Bala nagammal 41 F 399-0304 05.03.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 85 158 2 132/80 1 1 1 1 1 1 EP EP 13 14 1 1 1 1 1 1 1 1
37 Sumangali 31 F 399-4548 12.03.2015 2 1 2 2 1 1 2 2 NIL NIL NIL 55 150 1 130/90 1 1 2 2 1 2 ESP ESP 15 14 1 1 1 1 2 1 1 1
38 Mariyasugapriya 22 F 400-0215 20.03.2015 2 1 2 2 2 1 2 2 NIL NIL NIL 62 143 3 100/80 1 1 1 1 1 1 ESP ESP 12 11 1 1 2 2 1 1 1 1
39 Radhalakshmi 32 F 399-6176 14.03.2015 2 1 1 2 2 2 2 1 NIL NIL NIL 67 158 2 130/80 1 1 1 1 1 2 ESP ESP 16 18 1 1 1 1 1 1 1 1
40 Thavaselvi 36 F 399-6526 14.03.2015 2 1 1 2 1 2 2 2 THYROID THYROXINE NIL 71 156 2 110/70 1 1 1 1 1 2 ESP ESP 18 20 1 1 2 2 2 1 1 2
41 Muthulakshmi 24 F 400-1764 23.03.2015 2 1 2 2 1 2 1 2 NIL NIL NIL 63 151 2 110/70 1 1 2 2 1 1 EP EP 11 12 1 1 1 1 1 1 1 1
MASTER CHART 
42 Subbulakshmi 26 F 400-3277 25.03.2015 1 1 1 2 2 1 2 1 2 NIL NIL NIL 54 149 1 120/80 1 1 1 1 1 1 ESP ESP 18 19 2 2 2 2 2 1 1 1
43 Bhuvaneshwari 24 F 400-6407 31.03.2015 2 2 2 2 2 1 2 2 THYROID ELTROXIN NIL 62 148 2 110/70 1 1 1 1 1 2 ESP ESP 14 15 1 1 1 1 2 1 1 1
44 Deepak venkat kumar 25 M 400-9347 04.04.2015 2 1 1 2 2 2 2 2 NIL NIL NIL 90 177 2 130/90 1 1 2 1 1 1 ESP ESP 15 14 1 1 1 1 1 1 1 1
45 Pandeeswari 25 F 400-9403 04.04.2015 2 1 1 2 2 2 2 1 NIL NIL NIL 87 146 4 140/90 1 1 1 1 1 1 EP EP 16 14 1 1 1 1 1 1 1 1
46 Ramya 27 F 401-0077 06.04.2015 2 1 2 2 1 2 2 2 NIL NIL NIL 85 158 2 110/80 1 1 1 1 1 1 EP EP 15 16 1 1 1 1 1 1 1 1
47 Kaladevi 32 F 402-1727 23.04.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 54 148 1 120/80 1 1 2 2 1 1 ESP ESP 18 18 1 1 1 1 1 1 1 1
48 Meena.D 42 F 401-1919 08.04.2015 1 2 2 2 2 2 2 2 2 NIL NIL NIL 100 148 4 140/80 1 1 1 1 1 1 EP EP 10 18 1 1 1 1 2 1 1 1
49 Karuppayee 49 F 401-2808 09.04.215 2 1 2 2 1 2 1 2 HT Anti-HT NIL 90 152 4 114/84 1 1 1 1 1 1 ESP ESP 14 15 1 1 1 1 1 1 2 1
50 Nasriya 27 F 401-5055 13.04.2015 1 1 2 2 2 2 2 2 2 HYPOTHYROIDTHYRONORMNIL 71 160 2 130/90 1 1 1 1 1 1 EP EP 16 20 1 1 1 1 1 1 1 1
51 Ezhilarasi 28 F 401-5556 14.04.2015 1 1 1 2 2 1 1 1 2 NIL NIL NIL 64 148 2 90/70 1 1 2 2 1 1 ESP ESP 14 14 1 1 1 1 1 1 1 1
52 Nagajothi 23 F 401-5503 14.04.2015 2 1 1 2 2 2 1 2 NIL NIL NIL 50 155 1 130/70 1 1 2 2 1 1 ESP ESP 10 13 1 1 1 1 1 1 1 1
53 Dhanalakshmi 18 F 402-1932 23.04.2015 2 1 2 2 1 1 2 2 NIL NIL NIL 70 148 3 140/90 1 1 2 2 1 2 ESP ESP 11 12 1 1 1 1 2 1 1 2
54 Meena.M 39 F 402-5664 29.04.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 78 162.5 2 120/70 1 1 1 1 1 1 EP EP 16 17 1 1 1 1 2 1 1 1
55 Murugeswari 36 F 403-4873 12.05.2015 2 1 1 2 2 2 2 2 NIL NIL NIL 68 153 2 130/90 1 1 1 1 1 1 ESP ESP 12 12 1 1 1 1 2 1 1 1
56 Durga 31 F 403-7246 15.05.2015 2 1 2 1 2 2 2 2 NIL NIL NIL 87 150 4 150/100 1 1 1 1 1 1 ESP ESP 12 13 1 1 2 2 2 1 1 1
57 Sangeetha 25 F 403-8714 16.05.2015 1 1 1 1 2 1 2 2 2 NIL NIL NIL 64 148 2 130/70 1 1 1 1 1 1 ESP ESP 13 12 1 1 1 1 1 1 1 1
58 Bharathi 31 F 404-0473 19.05.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 65 149 2 110/70 1 1 1 1 1 1 ESP ESP 16 15 1 1 1 1 2 1 1 1
59 Pandi selvi 49 F 404-6761 26.05.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 50 151 1 150/80 1 1 1 1 1 1 EP ESP 12 14 1 1 1 2 1 1 1 1
60 Anandhajothi 28 F 404-9132 29.05.2015 2 1 2 2 2 2 2 2 NIL NIL NIL 60 152 2 110/70 1 1 1 1 1 1 ESP ESP 12 12 1 1 1 1 1 1 1 1
61 Renugadevi 24 F 404-9756 30.05.2015 1 1 1 2 2 2 2 2 2 NIL NIL NIL 65 148.5 2 110/70 1 1 1 1 1 1 ESP ESP 11 14 1 1 2 2 1 1 1 2
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1 and 2 normal 2 WR,DMX
1 and 2 normal 2 WR,DMX 22.01.2015 74 1 1 2 3 CP and OA CP and OA 2 2 2 2 DMX
1 and 2 2 WR,DMX 05.01.2015 56 1 1 1 1 RP RP 1 1 1 1 DMX 23.02.2015 56 1 1 1 1 N N 1 1 1 1 DMX
1 and 2 normal 1 DMX 24.01.2015 52 1 1 1 1 RP RP 1 1 1 1 DMX
1 and 2 normal 1 DMX 13.02.2015 47 1 1 1 1 RP RP 1 1 1 1 DMX
1 and 2 normal 1 DMX,IS 08.01.2015 55 1 1 1 1 RP RP 1 1 1 1 DMX,WR
1 1 HLTS,HLSS 2 DMX,WR 10.10.2015 60 1 1 1 1 CP CP 1 1 1 1 DMX,WR
1 normal 1 DMX
1 normal 1 DMX 22.01.2015 55 1 1 1 1 RP RP 1 1 1 1 DMX 13.02.2015 54 1 1 1 1 N N
1 normal 2 DMX,WR 07.08.2015 65 1 1 1 1 N N 1 1 1 1 WR
1 and 2 normal 1 DMX,WR 19.02.2015 75 1 1 1 1 RP RP 1 1 1 1 DMX,WR 27.03.2015 75 1 1 1 1 N N
1 and 2 HLTS,HLSS 1 DMX 20.02.2015 50 1 1 1 1 N N 1 1 1 1
1 normal 1 DMX,WR 18.02.2015 52 1 1 1 1 RP RP 1 1 1 1 DMX,WR 13.03.2015 52 1 1 1 1 N  N
1 and 2 1 DMX,WR 02.02.2015 62 1 1 1 1 RP RP 1 1 1 1 DMX,WR 05.03.2015 52 1 1 1 1 N N 1 1 1 DMX,IS
1 and 2 normal 1 DMX,WR 20.02.2015 73 1 1 1 1 RP RP 1 1 1 1 DMX,WR
1 1 and 2 normal 2 DMX,WR,IS 26.02.2015 68 1 1 1 1 RP RP 1 1 1 1 DMX,WR 19.03.2015 67 1 1 1 1 N N
1 2 DMX 02.03.2015 70 1 1 1 1 RP CP 1 1 1 1 DMX 08.03.2015 68 1 1 1 1 N N 1 1 1 1 WR
1 and 2 normal 2 DMX,WR 08.08.2015 1 1 1 N N 1 1 1 1 WR
1 and 2 normal 1 DMX, IS 12.03.2015 68 1 1 1 1 RP RP 1 1 1 1 DMX,WR 17.04.2015 67 1 1 1 1 N N 1 1 1 1 WR
1 and 2 normal 2 DMX 02.03.2015 51 1 1 1 1 ESP ESP 1 1 1 1 TOPIRAL 04.04.2015 54 1 1 1 1 RP RP 1 1 1 1 DMX
1 and 2 HLTS,HLSS 2 DMX,WR,IS 10.02.2015 83 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS 07.03.2015 82 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS
1 HLTS,HLSS,RTS,RSS 2 DMX,WR,IS 07.04.2015 64 1 1 1 1 N N 1 1 1 1 WR,IS
1 1 and 2 HLTS,HLSS,RTS,RSS 1 DMX,IS 27.03.2015 51 1 1 1 1 RP RP 1 1 1 1 DMX,IS 10.06.2015 51 1 1 1 1 N N 1 1 1 1 IS
1 and 2 B/L TSS 1 DMX,WR,IS 26.03.2015 70 1 1 1 1 RP RP 1 1 1 1 DMX,WR 15.05.2015 69 1 1 1 1 N N 1 1 1 1 WR
1 and 2 2 DMX,WR
1 and 2 normal 1 DMX 26.03.2015 64 1 1 1 1 RP RP 1 1 1 1 DMX,WR 11.04.2015 64 1 1 1 1 N N 1 1 1 1 WR
1 normal 1 DMX,IS 02.03.2015 50 1 1 1 1 ESP ESP 1 1 1 1 TOPIRAL 08.06.2015 52 1 1 1 1 RP RP 1 1 1 1 TOPIRAL
1 and 2 HRTS,HRSS,LTS, 2 ONSD 17.03.2015 78 1 1 1 1 CP CP 1 1 1 1 DMX,WR.IS 01.05.2015 78 1 1 1 1 CP CP 1 1 1 1 DMX,WR,IS
1 normal 1 DMX,WR,IS 25.02.2015 70 1 1 1 1 RP RP 1 1 1 1 DMX,WR.IS
1 and 2 normal 1 DMX,WR,IS
1 and 2 normal 1 DMX 19.03.2015 64 1 1 1 1 RP RP 1 1 1 1 DMX,WR 14.05.2015 62 1 1 1 1 N N 1 1 1 1 WR IS
1 2 DMX 13.03.2015 62 1 1 2 2 ESP ESP 1 1 1 1 DMX 18.04.2015 62 1 1 1 1 RP RP 1 1 1 1 DMX
1 normal 1 DMX 01.07.2015 60 1 1 1 1 RP RP 1 1 1 1 DMX 19.08.2015 60 1 1 1 1 N N 1 1 1 1 WR
1 and 2 normal 2 DMX,WR,IS 18.03.2015 88 1 1 1 1 RP RP 1 1 1 1 DMX.WR.IS 30.04.2015 88 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS
1 and 2 1 DMX,WR 18.03.2015 68 1 1 2 2 ESP ESP 1 1 1 1 DMX,WR
1 2 DMX,WR 21.03.2015 85 1 1 1 1 EP EP 1 1 1 1 DMX,WR 14.07.2015 83 1 1 1 1 N N 1 1 1 1 WR,IS
1 and 2 LTS,LSS 2 DMX,IS 16.04.2015 55 1 1 1 1 RP RP 1 1 1 1 DMX,IS 04.06.2015 55 1 1 1 1 N N 1 1 1 1 IS
1 HLTS,HLSS 2 DMX,WR 18.04.2015 58 1 1 1 1 RP RP 1 1 1 1 DMX,WR 18.04.2015 58 1 1 1 1 N N
1 HLTS,HLSS 1 DMX,WR 08.04.2015 66 1 1 1 1 RP RP 1 1 1 1 DMX,WR 13.06.2015 64 1 1 1 1 N N 1 1 1 1 WR
1 and 2 HLTS,HLSS 2 DMX,WR,IS 21.03.2015 71 1 1 1 1 ESP ESP 1 1 2 2 DMX,WR,IS 16.04.2015 70 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS
1 and 2 normal 1 DMX,WR 18.04.2015 63 1 1 1 1 EP EP 1 1 1 1 DMX,WR 15.04.2015 63 1 1 1 1 RP RP 1 1 1 1 DMX,WR 
1 1 and 2 HLTS,HLSS 2 MANNITOL 14.04.2015 54 1 1 2 2 RP RP 1 1 1 1 DMX 25.05.2015 54 1 1 1 1 N N 1 1 1 1
1 2 DMX,WR,IS 17.04.2015 64 1 1 1 1 ESP ESP 1 1 1 1 DMX,WR,IS 15.05.2015 61 1 1 1 1 RP RP 1 1 1 1 DMX,WR.IS
1 and 2 HLTS,HLSS 2 DMX,WR 25.04.2015 95 1 1 1 1 ESP ESP 1 1 2 2 DMX,WR 30.05.2015 95 1 1 1 1 RP RP 1 1 2 2 DMX.WR
1 and 2 HLTS,HLSS 1 DMX,WR 24.04.2015 86 1 1 1 1 RP RP 1 1 1 1 DMX,WR 16.05.2015 86 1 1 1 1 RP RP 1 1 1 1 DMX,WR
1 and 2 HLTS,HLSS 1 DMX,WR 15.04.2015 87 1 1 1 1 N N
1 and 2 normal 1 DMX 25.05.2015 54 1 1 1 1 RP RP 1 1 1 1 DMX 12.06.2015 53 1 1 1 1 N N 1 1 1 1
1 and 2 normal 2 DMX,WR,IS 15.05.2015 98 1 1 1 1 RP RP 1 1 1 1 TOPIRAL,WR 22.06.2015 98 1 1 1 1 RP RP 1 1 1 1 DMX,WR.IS
1 and 2 HLTS,HLSS 1 DMX,WR 16.05.2015 90 1 1 1 1 RP RP 1 1 1 1 DMX,WR 20.06.2015 90 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS
1 RTS 1 DMX,WR 14.05.2015 70 1 1 1 1 RP RP 1 1 1 1 DMX,WR 26.06.2015 70 1 1 1 1 N N
1 normal 1 DMX,WR 27.04.2015 64 1 1 1 1 ESP ESP 1 1 1 1 MANNITOL 25.06.2015 64 1 1 1 1 RP RP 1 1 1 1 DMX,WR
1 and 2 HLTS,HLSS 2 DMX 18.05.2015 50 1 1 1 1 ESP ESP 1 1 1 1 DMX 16.05.2015 50 1 1 1 1 RP RP 1 1 1 1 DMX
1 HLTS,HLSS 2 DMX,WR,IS 07.05.2015 70 1 1 1 1 ESP ESP 1 1 1 1 DMX,WR,IS 02.06.2015 70 1 1 1 1 RP RP 1 1 1 1 DMX,WR
1 HLTS,HLSS 2 DMX,WR,IS 20.05.2015 76 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS 23.07.2015 75 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS
1 and 2 LTS 2 DMX,WR,IS 11.07.2015 68 1 1 1 1 RP RP 1 1 1 1 DMX,WR,IS 18.08.2015 67 1 1 1 1 N N 1 1 1 1
1 and 2 normal 2 DMX.WR,IS 07.07.2015 87 1 1 1 1 ESP ESP 1 1 1 1 DMX,WR,IS 18.08.2015 85 1 1 1 1 ESP ESP 1 1 1 1 DMX,WR,IS
1 HLTS,HLSS 2 DMX,WR 03.06.2015 60 1 1 1 1 ESP ESP 1 1 1 1 DMX,WR 13.07.2015 60 1 1 1 1 RP RP 1 1 1 1 DMX,WR
1 HLTS,HLSS 1 DMX,WR,IS 25.06.2015 65 1 1 1 1 RP RP 1 1 1 1 DMX.WR.IS
1 normal 2 LP 27.04.2015 50 1 1 1 1 RP RP 1 1 1 1 DMX 28.05.2015 50 1 1 1 1 N N 1 1 1 1 DMX
1 and 2 normal 1 DMX,WR 23.06.2015 60 1 1 1 1 RP RP 1 1 1 1 DMX,WR 29.07.2015 60 1 1 1 1 N N 1 1 1 1 WR
1 normal 2 DMX,WR 25.06.2015 65 1 1 1 1 RP RP 1 1 1 1 DMX,WR 30.07.2015 63 1 1 1 1 RP RP 1 1 1 1 DMX,WR
